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imprinted genes is associated with imprinting disorders including Beckwith-Wiedemann syndrome (BWS)
and Silver-Russell syndrome (SRS) that exhibit abnormal growth phenotypes. These disorders are
associated with aberrant regulation of the imprinted loci in human 11p15 including the H19/IGF2 locus.
Finding various alterations of 11p15 associated with BWS and SRS inspires investigation of imprinting
mechanisms in human, which could provide insights into therapeutics. Mouse models have been
fundamental to the study of mechanisms of imprinting, serving as a proxy for the orthologous human
locus. However, elements that regulate genomic imprinting, the imprinting control regions (ICRs), often
diverge across species. Thus, it is essential to first understand whether the diverged ICR has a speciesspecific role in regulating imprinting. In Chapter 2, we generated a mouse in which the human ICR
sequence replaces the orthologous mouse ICR at the H19/Igf2 locus. We show that the imprinting
mechanism has partially diverged between mouse and human, depending on the parental origin of the
human ICR sequence in mouse. Additionally, we find that this mouse model is optimal for studying
specific alterations associated with BWS and SRS. The partially diverging imprinting mechanism between
mouse and human suggests that entirely human models are compelling alternatives. In Chapter 3, we
demonstrate the derivation of induced pluripotent stem cells (iPSCs) from BWS patient fibroblasts. We
find that the iPSCs exhibit proper epigenetic and transcriptional signatures of BWS. Although we find that
certain aspect of epigenetic perturbation is inevitable in our iPSCs, the consequence of this perturbation
remains unknown. Therefore, we propose that the iPSCs can be differentiated into clinically-relevant cell
types to elucidate molecular mechanisms leading to BWS. Overall, the work in this dissertation
underscores the versatile and complementary use of different model systems in investigating imprinting
mechanisms. In addition to serving as platforms to model imprinting disorders, these models provide
insights into the evolutionary perspective of imprinting as well as the significance of various epigenetic
mechanisms that regulate imprinting.
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ABSTRACT
DEVELOPING MODELS TO INVESTIGATE MECHANISMS OF GENOMIC IMPRINTING
Stellar K. Hur
Dr. Marisa S. Bartolomei

Genomic imprinting is a conserved, essential process in mammalian
development that regulates the expression of a small number of genes in a monoallelic,
parent-or-origin-specific manner. Misregulation of imprinted genes is associated with
imprinting disorders including Beckwith-Wiedemann syndrome (BWS) and Silver-Russell
syndrome (SRS) that exhibit abnormal growth phenotypes. These disorders are
associated with aberrant regulation of the imprinted loci in human 11p15 including the
H19/IGF2 locus. Finding various alterations of 11p15 associated with BWS and SRS
inspires investigation of imprinting mechanisms in human, which could provide insights
into therapeutics. Mouse models have been fundamental to the study of mechanisms of
imprinting, serving as a proxy for the orthologous human locus. However, elements that
regulate genomic imprinting, the imprinting control regions (ICRs), often diverge across
species. Thus, it is essential to first understand whether the diverged ICR has a speciesspecific role in regulating imprinting. In Chapter 2, we generated a mouse in which the
human ICR sequence replaces the orthologous mouse ICR at the H19/Igf2 locus. We
show that the imprinting mechanism has partially diverged between mouse and human,
depending on the parental origin of the human ICR sequence in mouse. Additionally, we
find that this mouse model is optimal for studying specific alterations associated with
BWS and SRS. The partially diverging imprinting mechanism between mouse and
human suggests that entirely human models are compelling alternatives. In Chapter 3,
we demonstrate the derivation of induced pluripotent stem cells (iPSCs) from BWS
patient fibroblasts. We find that the iPSCs exhibit proper epigenetic and transcriptional
v

signatures of BWS. Although we find that certain aspect of epigenetic perturbation is
inevitable in our iPSCs, the consequence of this perturbation remains unknown.
Therefore, we propose that the iPSCs can be differentiated into clinically-relevant cell
types to elucidate molecular mechanisms leading to BWS. Overall, the work in this
dissertation underscores the versatile and complementary use of different model
systems in investigating imprinting mechanisms. In addition to serving as platforms to
model imprinting disorders, these models provide insights into the evolutionary
perspective of imprinting as well as the significance of various epigenetic mechanisms
that regulate imprinting.
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CHAPTER 1.
INTRODUCTION
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1.1 Genomic imprinting
Two copies of autosomal genes exist in the mammalian genome, with each copy
inherited from the respective parental allele. The majority of mammalian genes are
simultaneously expressed or silenced from both parental alleles. However, a subset of
genes, known as imprinted genes, are uniquely regulated such that their expression
occurs in a monoallelic, parent-of-origin-specific manner (Figure 1.1).
Although imprinted genes comprise a small portion of the genome—about 150
imprinted genes have been identified in mouse and around half of them are conserved in
human—they are essential for normal embryonic development (Moore et al., 2015;
Plasschaert and Bartolomei, 2014). In 1984, androgenetic (two paternal pronuclei) and
gynogenetic (two maternal pronuclei) mouse embryos were generated by transplanting
pronuclei between one-cell-stage embryos. Here, uniparentally-derived embryos failed to
complete normal embryogenesis (Barton et al., 1984; McGrath and Solter, 1984). These
classic studies suggested that gene expression differences must exist between the
maternally and paternally inherited chromosomes and that normal development requires
both maternally and paternally expressed genes. Imprinted genes were unknown at the
time. However, subsequent studies in mouse models identified imprinted genes (for the
list of mouse imprinted genes see, http://www.mousebook.org/mousebookcatalogs/imprinting-resource) and illustrated that disruption of gene dosage or regulation
of these genes could severely impair embryonic growth, explaining the phenomena
observed in the androgenetic and gynogenetic embryos. Various human imprinting
disorders have also been described, with individuals displaying growth, neurological, and
metabolic clinical features (Kalish et al., 2014; Peters, 2014; Plasschaert and Bartolomei,
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2014). This emphasizes the conserved importance of correct regulation and expression
of imprinted genes for proper mammalian development.
1.1.1 Hypotheses on origins of genomic imprinting
Imprinted genes are conserved in mammals, and they have significantly
expanded in the therian lineage of mammals such as marsupials and eutherians
(placental mammals) (Renfree et al., 2013). Due to their complex nature of parental
allele-specific regulation and subsequent monoallelic expression, imprinted genes are
especially susceptible to various genetic/epigenetic challenges. Why, then, would
mammals develop such a costly mechanism of gene expression that could make the
organism more vulnerable to insults? To start addressing this question, it is worth
reviewing the two widely accepted hypotheses on the evolution of genomic imprinting.
The parental-conflict theory proposes that each parental genome has conflicting
“interests” in provisioning offspring. For example, paternally expressed genes prefer to
promote the growth of embryos to increase their genetic fitness. On the other hand,
maternally expressed genes try to suppress growth of embryos, allowing for more equal
allocation of limited maternal reproductive resources across successive pregnancies. In
support of this hypothesis, many paternally expressed imprinted genes such as Igf2,
Kcnq1ot1, Dlk1, Rasgrf1, Peg1, Peg3, Peg10, Rtl1, and Plagl1 promote growth, and the
maternally expressed imprinted genes, such as H19, Cdkn1c, Phlda2, Igf2r, and Grb10
suppress growth (Patten et al., 2014; Renfree et al., 2013).
Another hypothesis known as the maternal-offspring coadaptation theory
proposes that genomic imprinting has evolved in the context of coordinating the
maternal-offspring interactions to increase the fitness of offspring. The theory posits that
monoallelic (compared to biallelic) expression of genes allows for a more rapid
3

adaptation of important traits for provisioning offspring, such as embryonic growth and
maternal care. For example, the paternally expressed Peg3 gene is important not only
for proper maternal care and growth of the placenta by adult females, but also for
regulating ability of neonates to suckle (Isles, 2009; Renfree et al., 2013). Thus, this
gene might have evolved to be critical for facilitating the interaction between mom and
offspring, leading to imprinted, and thus fine-tuned expression. This hypothesis is further
supported by the fact that the majority of imprinted genes are expressed in placenta, a
vital tissue that connects physiology between mom and fetus (Renfree et al., 2013).
Each theory proposes a slightly distinct view on the origins of imprinting.
However, both theories share a common theme: imprinting must have evolved to
facilitate coordination and/or adaption of expression of a subset of genes in response to
the demands of complex biological processes required during mammalian development.
These intriguing theories underscore the need to further probe the evolutionary
perspective of imprinted genes at a molecular level. To this end, systematic investigation
on functions and mechanisms of imprinted genes in various mammalian species will be
valuable.
1.1.2 Regulation of cis-regulatory elements for genomic imprinting
Imprinted genes are typically found in clusters. Within a cluster, the parentalspecific expression of imprinted genes is coordinately regulated by a cis-regulatory
element, the imprinting control region (ICR). One hallmark feature of ICRs is parentalspecific differential DNA methylation (Abramowitz and Bartolomei, 2012). Proper
regulation of imprinted genes is highly dependent on the correct establishment,
maintenance, and erasure of the differential DNA methylation at ICRs (Figure 1.2)
Establishment
4

Studies in the mouse germ cells have established that ICRs acquire sperm- or
oocyte-specific DNA methylation pattern during gametogenesis (Figure 1.2) (Davis et al.,
1999; Lucifero et al., 2004). In both male and female germline, the de novo DNA
methyltransferase DNMT3a and its accessory protein DNMT3L are required for
establishing DNA methylation at ICRs (Bourc’his and Bestor, 2004; Bourc’his et al.,
2001; Kaneda et al., 2004; Kato et al., 2007). How these DNA methylation machinery
proteins are specifically recruited to the ICRs is currently unclear.
One hypothesis states that transcription at the ICRs is required for DNA
methylation establishment. Evidence to support this idea exists in both female and male
germ lines. At the Gnas imprinted locus, truncation of an upstream transcript Nesp (that
goes through the ICR of the locus) in the oocyte leads to loss of methylation at the locus
(Chotalia et al., 2009). This suggests that transcription through the ICR is necessary for
correctly establishing methylation at this locus. Transcripts crossing other maternally
methylated ICRs are also found at the Snrpn, Grb10, Igf2r, Impact, Kcnq1, and Zac1
imprinted loci (Chotalia et al., 2009; Mapendano et al., 2006). Similarly, transcription was
detected in the male germ cells at the H19/Igf2 locus, where the timing of transcription
correlated with that of ICR methylation establishment (Henckel et al., 2012). However,
the upstream signal for transcription in the germ cells as well as precise mechanism of
how transcription affects ICR methylation establishment remain to be determined.
Maintenance
Following fertilization in early embryos, ICRs resist the dynamic DNA methylation
reprogramming and preserve the parental-allele-specific methylation pattern in somatic
cells (Figure 1.2). To this end, the maternal factor DPPA3 was shown to maintain DNA
methylation at several ICRs by interacting with histone H3 lysine (K) residue 9 di5

methylation (H3K9me2) and/or by suppressing the activity of DNA demethylating teneleven translocation (TET) family enzymes (Bian and Yu, 2014; Nakamura et al., 2012).
The zinc finger protein ZFP57, which interacts with TRIM28, was shown to protect ICRs
from DNA demethylation (Li et al., 2008; Messerschmidt et al., 2014; Riso et al., 2016).
The DNA methylation maintenance enzyme DNMT1 methylates newly replicated DNA,
maintaining methylation at ICRs during cell divisions (Li et al., 1993).
In order to maintain the differentially methylated status of the ICRs, the
hypomethylated allele needs to be protected from aberrantly gaining methylation in
somatic cells. Activating post-translational histone modification marks seem to play
major role in this regard (discussed below). Yet, one trans factor that carries out this
function is the methylation-sensitive zinc-finger protein CTCF (Holwerda and de Laat,
2013). Inability to bind CTCF at the ICR of the H19/Igf2 imprinted locus caused aberrant
ICR hypermethylation (Engel et al., 2006). Mechanistically, a few groups proposed that
CTCF can activate PARP1, which can add ADP-ribose groups to DNMT1 and inactivate
the maintenance methyltransferase (Guastafierro et al., 2008; Yu et al., 2004; Zampieri
et al., 2012). However, this argument needs to be revisited because the presence or
absence of the ADP-ribolysated form of CTCF might be tissue-specific (Ideraabdullah et
al., 2014).
Erasure
In order to establish the sex-specific methylation pattern in mature gametes, it is
important that the established somatic ICR methylation is erased in primordial germ cells
(PGCs) (Figure 1.2). During this process, both passive (methylation that is lost due to
the absence of active DNMT1) and active mechanisms were shown to be involved.
Specifically, TET1 and TET2 enzymes are necessary to actively demethylate ICRs at
6

multiple imprinted loci (Messerschmidt et al., 2014). To do this, TET proteins catalyze
oxidation of methylated cytosine into hydroxymethylated cytosine, and possibly further
oxidized species, and the base excision repair pathway is activated to further remove the
oxidized forms of cytosine (Dawlaty et al., 2013; Hackett et al., 2013; Pastor et al., 2013).
Studying ICR methylation erasure and re-establishment requires access to early (and
limited) germ cells. Thus, most of the above findings were from mouse studies. Yet,
recent studies in human prenatal germ cells illustrate remarkable similarity in DNA
demethylation/re-methylation dynamics between the mouse and human germlines,
emphasizing that the ICR reprogramming is a conserved fundamental process in
mammalian development (Gkountela et al., 2015; Guo et al., 2015; Tang et al., 2015).
Histone modifications and genomic imprinting
In addition to DNA methylation, parental allele-specific histone modifications
have been described at ICRs in both somatic and germ cells (Delaval et al., 2007; Singh
et al., 2013; Stewart et al., 2015; Verona et al., 2008). Increasing evidence suggests that
histone modification composition can affect the extent of DNA methylation at ICRs
(Abramowitz and Bartolomei, 2012). For example, it was shown that oocytes lacking
KDM1B, a H3K4 demethylase, failed to establish DNA methylation at several ICRs
(Ciccone et al., 2009). This is consistent with the well-established antagonistic
relationship between DNA methylation and the activating histone marks such as
H3K4me2 and H3K4me3 at both imprinted and non-imprinted loci (Meissner et al., 2008;
Ooi et al., 2007; Singh et al., 2013; Stewart et al., 2015). Importantly, Hajkova et al.
illustrated that extensive histone modification erasure occurs in PGCs (Hajkova et al.,
2008), suggesting that epigenetic reprogramming during this stage also occurs at a
chromatin level. The mechanisms by which histone modifications are deposited or
7

removed at ICRs are currently unknown. However, it is quite evident that proper
establishment and erasure of histone modifications at ICRs is equally vital as that of
DNA methylation for correct regulation of imprinting. Indeed, various imprinting disorders
are associated with altered histone modification profiles at ICRs (Nativio et al., 2011).
Which epigenetic mark (i.e. DNA methylation or histone modifications) works as
the “primary” signal for distinctly marking each parental allele to regulate imprinted gene
expression is an active area of research in the field. This could be locus-dependent.
Overall, understanding the relationship between the two epigenetic modifications in
regulating genomic imprinting will tremendously contribute to the field of imprinting.
1.1.3 Evolution and conservation of imprinting control regions (ICRs)
Imprinted genes are conserved in mammals and differentially methylated ICRs
play fundamental roles in genomic imprinting. This has led researchers to elucidate the
molecular bases of the evolution of imprinted genes by examining orthologous ICR
sequences between different mammalian species. Comparative sequence analyses
conducted by Suzuki et al. illustrated that novel CpG-rich sequences (which form the
now called ICRs) emerged at different time points during mammalian evolution in various
imprinted regions. These sequences emerged predominantly during eutherian evolution
following the marsupial-eutherian split, suggestive of the evolutionary timeline during
which functional imprinted genes were established (Suzuki et al., 2011).
One potential mechanism by which the novel CpG-rich sequences (or ICRs) are
gained is via retrotransposition. This hypothesis stems from the fact that these
sequences are 1) similar to transposable elements in that they are enriched with CpG
sites and 2) subject to DNA methylation in the gametes, a mechanism reminiscent of the
conserved epigenetic host defense mechanism against foreign DNA (e.g., transposable
8

elements) in the germ cells (Barlow, 1993; McDonald et al., 2005). In fact, previous
reports have found evidences of retrotransposition of several imprinted genes including
Peg10, Mcts2, Nap1L5, Inpp5f_v2, U2af1-rs1, and Nnat. These studies lead to the
speculation that ICRs likely emerged at the same time as the retrotransposition of each
imprinted gene (Suzuki et al., 2011). However, not all currently identified ICRs display
evidence of retrotransposition, suggesting that other unknown mechanisms could
promote acquisition of these regulatory elements in imprinted regions.
Interestingly, after the novel CpG-rich sequences in imprinted regions were
acquired, some underwent genetic and/or epigenetic changes over time. For instance,
the CpG-rich sequences of Slc38a4, Snrpn, and Gnas became differentially methylated
only in the eutherian lineage (thus fulfilling the prerequisites of being designated as
ICRs) although the CpG-rich sequences were established earlier. In addition, the
number of CpG sites within the orthologous ICR sequences of Grb10 increased during
mammalian evolution, while overall sequence homology was maintained (Suzuki et al.,
2011). These observations suggest that some selective pressure could have acted on
ICRs and/or imprinted regions, contributing to their evolution at a molecular level.
Consistent with the fact that imprinted genes and ICRs have greatly expanded
during eutherian evolution, mouse and human exhibit extensive conservation of
imprinted genes by sharing key features of imprinting and spatial organization of cisregulatory elements. However, ICRs are often divergent between human and mouse,
raising an interesting question of whether the diverged ICR sequences have any
functional species-specific significance. One approach that can be exploited to address
this question is to substitute the ICR sequence of one species with that of another
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species at the orthologous locus. We took this strategy in specifically probing the
H19/Igf2 imprinted locus (described in detail below), as discussed in Chapter 2.
1.2 Imprinted clusters on mouse distal chromosome 7/human 11p15
Two highly conserved imprinted clusters—H19/Igf2 and Cdkn1c/Kcnq1ot1 loci—
are located in mouse distal chromosome 7 which is syntenic to the human 11p15 region
(Figure 1.3 and Figure 1.4). These chromosomal regions epitomize genomic imprinting
for various reasons: 1) Both maternally and paternally methylated ICRs are found, 2) the
two major mechanisms of imprinting—insulator model and long non-coding RNA
(lncRNA) model—are used, 3) genetic/epigenetic alterations affecting the ICRs are
associated with major growth-related imprinting disorders. Thus, various scientific
endeavors were pursued to elucidate genomic imprinting in these regions. Most notably,
these imprinted regions are involved in growth regulation in both normal and pathological
contexts. Therefore, mechanisms of imprinting at the H19/Igf2 and Cdkn1c/Kcnq1ot1 loci
as well as their involvement in growth regulation are discussed in detail below.
1.2.1 H19/Igf2 imprinted locus
H19
H19 is a maternally expressed ~2.5kb lncRNA (Bartolomei et al., 1991) and is
one of the few imprinted genes conserved in marsupials. Although the extent of
sequence similarity between the marsupial and eutherian H19 gene is very low, the
exonal structure is highly conserved across therians (Figure 1.5A). In fact, H19/Igf2 is
the most ancient imprinted cluster identified to date (Smits et al., 2008). Despite the wellknown conservation of the gene, functions of H19 in different tissues/physiological
contexts seem to vary and remain to be further investigated. H19 is abundantly
expressed in mouse embryonic endodermal and mesodermal lineage tissues as well as
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in placenta, but expression rapidly declines after birth (Bartolomei et al., 1991; Milligan et
al., 2000). The best characterized function of H19 is its role in growth suppression during
fetal and placental development; mouse models lacking H19 display embryonic and
placental overgrowth with no other apparent phenotypes (Ripoche et al., 1997; Schmidt
et al., 1999).
The mechanism by which H19 lncRNA regulates growth remains largely
unknown. Yet, one recent study proposed that H19 suppresses placental growth via
maternally expressed microRNA (miR)-675 encoded within the first exon of H19 (Figure
1.5A) (Keniry et al., 2012). Here, two distinct miRs—miR-675-5p and miR-675-3p—are
produced (Figure 1.5B). miR-675 is most highly expressed in mouse late gestation
placenta (its expression peaks around embryonic day (E) 19.5) while it is lowly
expressed in other fetal tissues (Keniry et al., 2012). Such a dissimilar spatiotemporal
expression pattern between H19 and miR-675 suggests that despite sharing the same
transcription unit and the seemingly overlapping role in growth suppression, expression
of each factor might be regulated and function via different mechanisms. Keniry et al.
suggests RNA-binding protein HuR as one factor that regulates processing of miR-675
from H19 (Keniry et al., 2012). This study also demonstrated that overexpression of miR675 in various embryonic and extra-embryonic cell lines reduced cell proliferation (Keniry
et al., 2012). However, testing the role of miR-675 independent of H19 needs to be
carried out in vivo to dissect the potentially distinct role of each factor in growth
regulation during development.
H19 has also been suggested to regulate a network of imprinted genes (known
as the imprinted gene network, IGN) in trans to control embryonic growth (Gabory et al.,
2009; Varrault et al., 2006). This was hypothesized because modulation of H19 altered
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expression of other growth-related imprinted genes such as Igf2, Dlk1, Rtl1, Gnas, Peg3,
Slc38a4, Cdkn1c, and Igf2r (Gabory et al., 2009). The extent to which the changes in the
IGN gene expression is directly/indirectly regulated by H19 is unclear. Monnier et al.
showed that H19 can physically interact with the methylated CpG binding protein MBD1
and repress a subset of IGN genes by modulating H3K9me2 level in vitro (Monnier et al.,
2013). Yet, this experiment requires validation in vivo. Moreover, whether such a change
in imprinted gene expression is merely a secondary effect caused by changes in cell
composition and/or number needs to be validated at a single cell level. Nevertheless, the
idea of coordinate regulation of imprinted genes is gaining attention, as it has been
described during muscle regeneration and lung stem cell self-renewal as well (Al Adhami
et al., 2015; Patten et al., 2016; Zacharek et al., 2011). Perhaps this concept fits well
with the original hypotheses on genomic imprinting as a way to fine-tune complex gene
expression in mammals.
Igf2
Igf2 is a paternally expressed fetal growth factor. Similar to H19, Igf2 is
ubiquitously expressed in embryonic and placental tissues (Engström et al., 1998). IGF2
binds to the non-signaling receptor IGF2R (which is also imprinted) with high affinity,
although it can also bind to signaling receptors such as IGF1R and the insulin receptor
with lower affinity (Bergman et al., 2013). IGF2R acts as a growth suppressor by
sequestering and degrading circulating IGF2 (Scott and Weiss, 2000), whereas IGF2
binding to IGF1R promotes growth during fetal development (Baker et al., 1993). The
fact that IGF2 plays a pivotal role in embryonic growth is evident in the Igf2 knock-out
mouse models, where mice display embryonic and placental growth restriction with no
other apparent phenotype (DeChiara et al., 1990; DeChiara et al., 1991).
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Regulation of imprinting at the H19/Igf2 locus
Imprinting at the H19/Igf2 locus is regulated by a model known as the insulator
model (Figure 1.3). This model illustrates that an insulator/enhancer blocker is formed at
the ICR in an allele-specific manner, preventing the interactions between enhancers and
promoters. Previous studies demonstrated that H19 and Igf2 share a set of conserved
mesodermal and endodermal enhancers located downstream of H19 (Ishihara et al.,
2000; Kaffer et al., 2001; Leighton et al., 1995a). The ICR at this locus, called IC1, is
located between H19 and Igf2. On the maternal allele, the unmethylated IC1 forms an
insulator by interacting with CTCF (Bell and Felsenfeld, 2000). This prevents the
interaction of the Igf2 promoters with the downstream enhancers, silencing Igf2
expression; because the H19 promoter is accessible to the enhancers, only H19 is
expressed on the maternal allele. On the paternal allele, IC1 is DNA methylated and
blocks CTCF binding; thus, the insulator does not form and Igf2 is expressed. The IC1
also plays a role in silencing paternal H19 expression, by spreading methylation across
the H19 promoter (Tremblay et al., 1997).
Various mouse models that carry mutations at IC1 have supported the essential
role of DNA methylation and CTCF binding for proper insulator function of IC1. When the
paternal IC1 was mutated at CpG sites to deplete DNA methylation, ectopic binding of
CTCF was observed on the paternal allele, leading to biallelic H19 expression and
reduced Igf2 expression (Engel et al., 2004). When the CTCF binding sites were deleted
on the maternal IC1 to disrupt the insulator, biallelic Igf2 expression and reduced H19
expression was observed (Engel et al., 2006). These studies demonstrate that any
insults leading to aberrant DNA methylation or CTCF binding at the IC1 can disrupt
imprinted expression at the H19/Igf2 locus.
13

Other trans-factors have also been proposed to maintain proper insulator
function of IC1, although these hypotheses mostly remain controversial. One such factor
is ZFP57, whose binding motifs reside in both mouse and human IC1. ZFP57 was
shown to play a role in maintaining DNA methylation at imprinted loci such as Dlk1-Dio3,
Peg1, Peg3, and Nnat (Li et al., 2008). Conflicting results were presented by two
studies: IC1 methylation was unaffected in ZFP57-deficient mice yet affected in the
zfp57-null mouse embryonic stem cells (ESCs) (Li et al., 2008; Riso et al., 2016). In
addition, patients that have mutations in ZFP57 do not display methylation defects at IC1
(Mackay et al., 2008). Thus, further studies are warranted to assess the role of ZFP57 in
IC1 insulator function.
Pluripotency factors such as OCT4 and SOX2 are also proposed as candidates
for regulating IC1 function. OCT4-and SOX2-binding sites are present at both mouse
and human IC1 (Shmela and Gicquel, 2013). OCT4-binding sites at the mouse IC1 were
shown to be important for maintaining hypomethylated state of IC1 in mouse embryonal
carcinoma cell line (Hori et al., 2002). However, a mouse model that harbors 0.9kb IC1
fragment deletion (which also deleted the OCT4-binding sites) showed no perturbation of
imprinting at the locus (Ideraabdullah et al., 2011). Interestingly, a mouse model with
endogenous OCT4 binding site mutations at the IC1 displayed partial gain of methylation
during post-zygotic stages, without affecting monoallelic H19 and Igf2 expression
(Zimmerman et al., 2013). Therefore, the extent to which OCT4-and/or SOX2-binding
sites contribute to the insulator function of IC1 awaits further investigation.
H19/Igf2 locus is the only imprinted locus that uses a well-defined insulator
model of imprinting. Although CTCF binding sites have been described at other
imprinted regions including the Grb10, Rasgrf1, Dlk1-Dio3, and Cdkn1c/Kcnq1ot1 loci
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(Lin et al., 2011; Plasschaert and Bartolomei, 2014; Yoon et al., 2005), it is unknown
whether these loci utilize the similar insulator model as the H19/Igf2 locus.
1.2.2 Cdkn1c/Kcnq1ot1 imprinted locus
The Cdkn1c/Kcnq1ot1 imprinted locus includes at least 8-10 maternally
expressed protein coding genes (Figure 1.4). Some of these genes are ubiquitously
imprinted whereas others are imprinted specifically in placenta. A few genes implicated
in growth regulation are discussed below.
Cdkn1c
Cdkn1c is a maternally expressed cyclin-dependent kinase inhibitor. The gene is
expressed and imprinted in derivatives of all three germ lineages during mouse
embryonic development, primarily in cells that are exiting the cell cycle (Tunster et al.,
2011). Cdkn1c is a major growth suppressor in the Cdkn1c/Kcnq1ot1 imprinted cluster.
Mice lacking Cdkn1c displayed embryonic and placental overgrowth during mid-late
gestation (Tunster et al., 2011). Overexpression of Cdkn1c alone in transgenic mice
could lead to embryonic lethality. In the same study, the level of the fetal growth factor
Igf1 transcript was concomitantly altered upon changes in the dosage of Cdkn1c
(Andrews et al., 2007), suggesting that growth regulation of Cdkn1c could in part be
achieved via Igf1. Other suggested roles of Cdkn1c during development include cell
differentiation, migration, and modification of actin cytoskeleton (Andrews et al., 2007;
Hatada and Mukai, 1995; Tunster et al., 2011).
Ascl2 and Phlda2
Ascl2 and Phlda2 are maternally expressed genes that are exclusively imprinted
and/or preferentially expressed in placenta. Ascl2 is a transcription factor that is
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essential for cell proliferation in placenta (Guillemot et al., 1995), whereas Phlda2 is a
cytoplasmic protein that negatively regulates placental growth (Frank et al., 2002).
Because placenta is an essential organ for maternal-offspring nutrient exchange (Frost
and Moore, 2010), proper regulation of placental development is indispensable for
normal embryonic growth.
Kcnq1ot1 and the regulation of imprinting at the Cdkn1c/Kcnq1ot1 locus
In some imprinted regions, including the Cdkn1c/Kcnq1ot1, Igf2r, and Snrpn loci,
parental allele-specific lncRNAs have been identified and were shown to play a role in
silencing genes in cis (Lee and Bartolomei, 2013). This mechanism of imprinting is
known as the lncRNA model and is more widely used than the insulator model. In this
model, lncRNAs are expressed from the ICRs and this expression depends on the
methylated status of the ICRs (i.e. when ICR is methylated, lncRNA is silenced; when
unmethylated, lncRNA is expressed) (Figure 1.4). Subsequently, lncRNAs can silence
the genes in cis by interfering with transcription of the nearby genes or by promoting
repressive chromatin environment at the imprinted locus (Lee and Bartolomei, 2013).
Kcnq1ot1 is a ~91kb lncRNA expressed from the paternal allele that has no
known physiological function (Kanduri, 2011). Its transcription initiates from the ICR of
the Cdkn1c/Kcnq1ot1 locus, called IC2, in an antisense orientation. IC2 is located in
intron 10 of the Kcnq1 gene and is methylated on the maternal allele; thus, Kcnq1ot1 is
silenced on the maternal allele and the cis-genes are expressed (Kanduri, 2011).
Although Kcnq1ot1 is ubiquitously expressed, its mode of action seems to be
tissue-specific (i.e. placenta-specific and ubiquitously imprinted genes seem to be
regulated differently) (Umlauf et al., 2004; Wagschal et al., 2008). Previous studies
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proposed that Kcnq1ot1 can perform bi-directional silencing on the paternal allele by
modulating histone modification enrichment at the placenta-specific imprinted genes at
the locus. These genes are enriched with the paternal allele-specific H3K27me3 and
H3K9me2 (Lewis et al., 2004; Umlauf et al., 2004). In the Kcnq1ot1 truncation mutant,
enrichment of H3K27me3 was affected at these sites (Pandey et al., 2008).
Coimmunoprecipitation and RNA fluorescent in situ hybridization (FISH) experiments
suggested that Kcnq1ot1 potentially interacts with various histone modifiers such as
G9A (H3K9 methyltransferase), PRC2 complex (catalyzes H3K27 methylation), and
RNF2 (ubiquitin E3 ligase) (Pandey et al., 2008; Terranova et al., 2008). Consistently,
when G9A was knocked out, partial loss of H3K9me2 and H3K9me3 at the locus was
observed (Wagschal et al., 2008). These results suggest that Kcnq1ot1 regulates
imprinting in placenta by interacting with various histone modifiers.
On the other hand, Kcnq1ot1 seems favor a different epigenetic modification—
DNA methylation—in silencing the ubiquitously imprinted genes at the locus, such as
Cdkn1c and Slc22a18 (Lewis et al., 2004). To support this idea, somatically established
differentially DNA methylated regions (DMRs) are only found around Cdkn1c and
Slc22a18, but not at the placenta-specific imprinted genes (Lewis et al., 2004).
Mohammad et al. illustrated that Kcnq1ot1 can recruit DNMT1 to these DMRs to
maintain methylation (Mohammad et al., 2010). In addition, both Cdkn1c and Slc22a18
were biallelically expressed in Dnmt1-null embryos and placentas. Notably, monoallelic
expression of the placenta-specific imprinted genes Cd81, Osbpl5, and Tssc4 was
barely affected by loss of DNMT1, suggesting that imprinting in placenta minimally relies
on DNA methylation (Lewis et al., 2004).
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It is unlikely that all lncRNA imprinting models function via altering chromatin
environment. For example, Airn is a paternally expressed antisense lncRNA at the Igf2r
imprinted locus. One of the cis genes Airn silences is the growth regulator Igf2r. Latos et
al. showed that Airn silences Igf2r by transcriptional interference, by reducing
recruitment of RNA polymerase II to the Igf2r promoter (Latos et al., 2012). Thus, in this
case, the act of transcription per se is more important for imprinting than the lncRNA
transcript itself.
In conclusion, the lncRNA model of imprinting seems to be more versatile in its
mechanisms of action and is employed by more imprinted loci. Further studies should
address questions such as how lncRNAs find their targets, how lncRNAs interact with
epigenetic modifiers or transcription machinery proteins, and how lncRNA-driven tissuespecific imprinting is established and maintained.
1.3 Human disorders associated with 11p15
Mouse models have held great value for investigating mammalian imprinting
mechanisms. Nevertheless, the recent identification of various alterations at the 11p15
region in human imprinting disorder patients has raised new questions about how
imprinting functions in human health and disease. The ability to model the newly
discovered alterations will provide additional insights into human imprinting mechanisms
and potentially assist in therapeutic advances for these disorders. Furthermore,
comparing the phenotypes of the patients to those of mouse models with similar
mutations provides clues about the extent to which imprinting mechanisms are
conserved between the two species.
As mentioned above, the human 11p15 region is essential for growth regulation.
Consistently, two major growth-related imprinting disorders—Beckwith-Wiedemann
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syndrome (BWS) and Silver Russell syndrome (SRS)—are associated with
misregulation of imprinting in this region. Clinical features and molecular etiologies of
both disorders are discussed below.
1.3.1 Clinical features and occurrence rate of BWS and SRS
BWS (OMIM 130650) is a pediatric overgrowth disorder with an estimated
frequency of 1/10,500 per live births, affecting males and females equally, making it the
most common imprinting disorder (Choufani et al., 2013; personal communication with
Jennifer Kalish, MD, PhD at Children’s hospital of Philadelphia (CHOP)). Major clinical
features include enlarged tongue, hemihyperplasia (asymmetric overgrowth), and
abdominal wall defects (Weksberg et al., 2010). Notably, some BWS individuals develop
embryonal tumors, most commonly Wilms tumor (kidney cancer) and hepatoblastoma
(liver cancer) (Choufani et al., 2013).
SRS (OMIM 180860) is a rarer pediatric growth failure disorder with more than
400 cases being reported since its first description in 1953 (Silver et al., 1953; Russell,
1954; Ishida, 2016). Major clinical features include intrauterine growth restriction,
hemihypoplasia (asymmetric undergrowth), and relative macrocephaly (Ishida, 2016).
In both BWS and SRS, the reported occurrence rate could be an underestimation.
Improved sensitivity of molecular diagnostic techniques used in the clinic to analyze
DNA methylation aberration, chromosomal rearrangements, and percent mosaicism of
affected cells has increased the chances of detecting understated molecular signatures
in the patients. In addition, the spectrum of clinical phenotypes is now better
characterized, which enables clinicians to recognize individuals with subtler clinical
features (personal communication with Jennifer Kalish, MD, PhD at CHOP). These
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improvements in the medical setting are invaluable to the patients and their families and
widen opportunities to dissect human imprinting mechanisms.
BWS and SRS patients display a wide spectrum of clinical phenotypes (Ishida,
2016; Weksberg et al., 2010). This may occur either as a consequence of the mosaic
distribution of affected cells or the genetic background of the individuals (Beygo et al.,
2013; Kalish et al., 2013; Kannenberg et al., 2012). Thus, studies of imprinting
mechanisms in the context of human disorders need to control for the mosaicism and
genetic background in the patients. One way such issues can be addressed is by
deriving patient-specific induced pluripotent stem cells (iPSC) lines, as discussed in
Chapter 3.
1.3.2 Molecular etiology of BWS
Various BWS-associated molecular alterations have been described, including
genetic and epigenetic alterations and chromosomal abnormalities (Figure 1.6) (Soejima
and Higashimoto, 2013; Weksberg et al., 2010).
Alterations in the CDKN1C/KCNQ1OT1 locus are prevalent among BWS
individuals. In fact, the most common alteration found in BWS population (~50%) is IC2
hypomethylation (Figure 1.6). Because IC2 is never completely hypomethylated in each
patient, the epimutation is assumed to occur mosaically, which is a common
characteristic of majority of epimutations found in imprinting disorders (Soejima and
Higashimoto, 2013; Ishida, 2016). IC2 hypomethylation is accompanied by loss of H3K9
methylation at IC2, biallelic KCNQ1OT1 expression, and loss of CDKN1C expression
(Diaz-Meyer et al., 2003; Higashimoto et al., 2003). This phenotype can be explained by
the Cdkn1c/Kcnq1ot1 imprinting mechanism that was elucidated in mouse models,
suggesting that a similar imprinting mechanism is used in humans. The overgrowth
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phenotype found in these patients is most likely driven by loss of CDKN1C, as various
CDKN1C mutations leading to loss of function of the protein are also found in small
subset (~5%) of BWS patients (Hatada et al., 1996; Romanelli et al., 2010).
Although alterations involving the H19/IGF2 locus are less common, they are
associated with increased risk of tumor development. About 2-7% of BWS cases display
IC1 hypermethylation (Soejima and Higashimoto, 2013). Notably, an increasing number
of studies are finding genetic alterations associated with IC1 hypermethylation (Figure
1.6 and Figure 1.7). One type of mutation is IC1 microdeletions that remove different
sequences and numbers of CTCF binding sites (CTS). In these patients, when the
mutation is maternally inherited, IGF2 is biallelically expressed and H19 expression is
reduced, suggestive of a loss of insulator function (Beygo et al., 2013; Prawitt et al.,
2005; Sparago et al., 2004). These phenotypes are reminiscent of the mouse models
with partial deletions of the IC1 sequence. In these models, IC1 was hypermethylated at
the remaining IC1 and biallelic Igf2 expression was observed upon maternal inheritance
of the mutant allele (Engel et al., 2006; Thorvaldsen et al., 1998). These results suggest
that the imprinting mechanism at the H19/IGF2 locus is largely conserved between
human and mouse.
Point mutations of the OCT4-SOX2-binding motif have also been identified
among BWS individuals with IC1 hypermethylation (Figure 1.7). Maternal transmission of
the mutant alleles is associated with clinical phenotypes in the patients (Demars et al.,
2010; Habib et al., 2014; Poole et al., 2012). As mentioned previously, studies
investigating the role of the mouse OCT4-binding sites in the insulator function of IC1
presented ambiguous results. Similarly, inconsistent arguments were made regarding
the role of human OCT4-binding sites in the function of IC1. Mutating the OCT4-binding
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sites on human IC1 minimally affected the enhancer-blocking and CTCF-binding
activities of IC1 in vitro (Beygo et al., 2013). In contrast, human IC1 sequence with
OCT4-binding site mutation impaired the ability of IC1 to bind human OCT4/SOX2
proteins in vitro, suggesting that the binding of these proteins has a functional role at IC1
(Demars et al., 2010). Overall, the contribution of OCT-SOX-binding sites to the insulator
function of IC1 remains unknown in both mouse and human. However, it is possible that
1) the ability of OCT4-SOX2-binding motifs to control IC1 methylation depend on the
non-conserved sequence of IC1 between mouse and human and thus be speciesspecific 2) OCT4 mutations may predispose patients to BWS via unidentified mechanism
(Zimmerman et al., 2013).
Lastly, paternal uniparental isodisomy of chromosome 11 (pUPD11) is found in
about 20% of BWS cases and normally includes both H19/IGF2 and
CDKN1C/KCNQ1OT1 loci. pUPD11 occurs when part or entire of the maternal
chromosome 11 is lost in a single cell. To repair the missing chromosome or
chromosome portion, a duplication of the corresponding region of the paternal
chromosome occurs. This rescue event leads to both copies of chromosome 11 having
the paternal epigenotype, resulting in IC1 hypermethylation, IC2 hypomethylation,
increased IGF2 expression, and reduced H19 and CDKN1C expression (Kalish et al.,
2014)) (Figure 1.8). The majority of pUPD11 BWS cases display mosaicism, indicating
that these alterations arise post-zygotically (Kalish et al., 2014). Interestingly, pUPD11
patients are more predisposed to tumor development (Kalish et al., 2014). Despite being
one of the common origins of BWS, no models to study pUPD11 exist in the field. This is
largely due to the difficulty of engineering such chromosomal lesions as well as the
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mosaic nature of UPD in patient samples. In Chapter 3, we describe a human cell-based
model system that can be used to investigate pUPD11 and BWS.
1.3.3 Molecular etiology of SRS
The most common alteration associated with SRS is IC1 hypomethylation (Figure
1.6) (Ishida, 2016). Given the established model of imprinting at the H19/Igf2 locus in
mouse, this epimutation is proposed to reduce IGF2 expression and increase H19
expression. Indeed, a mouse model depleted of methylation at IC1 had biallelic H19
expression, reduced Igf2 expression, and 40% reduction in the size of the animals
(Engel et al., 2004). Consistently, Gicquel et al. observed that patients with IC1
hypomethylation exhibited reduced IGF2 and biallelic H19 expression (Gicquel et al.,
2005). However, results from other human studies have led to ambiguous conclusions
about the exact mechanisms underlying SRS with IC1 hypomethylation. For example,
Azzi et al. did not observe difference in IGF2 expression between IC1 hypomethylation
and unaffected patients’ fibroblasts. Moreover, total H19 expression level did not
correlate with the degree of IC1 methylation (Azzi et al., 2014). Heckmann et al. did not
detect differences in IGF2 protein secretion nor H19 expression between IC1
hypomethylation and unaffected fibroblasts; instead, cells with IC1 hypomethylation
exhibited aberrantly expressed genes involved in cell proliferation, cell cycle control, and
timing of mitosis (Heckmann et al., 2015). Such discrepancies between human studies
could be due to mosaic nature of the epimutation as well as the use of disease-irrelevant
tissues, such as blood and fibroblasts, where H19 and IGF2 are lowly expressed.
Maternal UPD of chromosome 7 (mUPD7) accounts for ~10% of SRS cases
(Figure 1.6) (Bartholdi et al., 2009). mUPD7 encompasses imprinted genes such as
GRB10, CPA4, MEST, KLF4, MEST1T1, and COPG21T1 (Ishida, 2016). However, no
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known single mutation of any of these genes has been identified to date, although
possible involvement of epimutations cannot be excluded (Ishida, 2016). Of note,
maternally expressed Grb10 suppresses growth in the mouse (Plasschaert and
Bartolomei, 2014). In study by Leach et al., individuals with mUPD7 in which GRB10
was excluded from the duplicated region, did not display SRS growth failure phenotypes;
this implies that GRB10 might be involved in pathogenesis of SRS (Leach et al., 2007).
1.4 Challenges in studying imprinting mechanisms
Mouse models are extremely advantageous in investigating imprinting
mechanisms because parent-of-origin transmission of an imprinted allele can be tested.
Moreover, access to early germ cells such as PGCs allows monitoring of epigenetic
reprogramming at ICRs, the most essential aspect of imprinting regulation. However,
mouse models with endogenous ICR mutations often do not fully recapitulate human
phenotypes associated with mutations at the orthologous locus. Various Cdkn1c loss of
function mouse models do not present neonatal overgrowth phenotype of BWS (Tunster
et al., 2011). A mouse model that carries 1.3kb deletion at IC1, generated to model IC1
microdeletions in human, exhibits biallelic Igf2 expression with no changes in IC1
methylation (Ideraabdullah et al., 2014). Furthermore, biallelic Igf2 expression is only
observed in tissues of mesodermal origin (Ideraabdullah et al., 2014). Imprinting
mechanisms seem to be generally conserved between mouse and human. However, it is
possible that across evolution from mouse to human, certain aspects of imprinting have
diverged. Tunster et al. speculate that differences in the reproductive strategies (i.e.
multiparous in mouse and singleton pregnancy in human) might have driven the
divergence (Tunster et al., 2011). Thus, mouse models alone might not be sufficient to
fully comprehend human imprinting mechanisms.
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As a complementary approach, various studies were conducted using patient
samples to investigate imprinting mechanisms and/or disease etiology. However, human
studies have led to varying conclusions. Such discrepancy can result from 1) the use of
blood and/or fibroblasts samples that are often irrelevant to disease (by expressing
genes of interest at a very low level), 2) mosaic nature of the genetic mutations or
epimutations. In line with this idea, studies have shown that the degree of DNA
methylation alterations in BWS and SRS can be tissue-, cell-, and CpG site-specific,
regardless of presence of genetic lesions (Beygo et al., 2013; Kannenberg et al., 2012).
Therefore, model systems in which mosaicism can be controlled in a disease-relevant
cell types are best suited to investigate mechanisms of imprinting.
The overall goal of this dissertation is to develop and explore model systems to
study imprinting mechanisms. We have developed both in vivo and in vitro models with
initial interest in modeling human imprinting mechanisms, focusing on the human 11p15
imprinted loci. Beyond serving as platforms to study imprinting mechanisms, these
models allowed us to speculate on the evolutionary perspective of imprinting as well as
epigenetic vulnerability in cell culture models.
Chapter 2 describes an in vivo mouse model where human IC1 sequence
replaces the orthologous mouse sequence. We find that the human and mouse
imprinting mechanism at the H19/IGF2 locus has partially diverged. We also propose
that this mouse model may serve to study mechanisms of IC1 hypomethylation
associated with SRS. Chapter 3 describes an iPSC model derived from the fibroblasts of
pUPD11 patients with BWS. These cell lines display the expected and stable epigenetic
signatures at the pUPD11-relevant region, making them suitable models to study
mechanisms underlying pUPD11 leading to BWS. However, we find that one imprinted
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locus that frequently exhibits loss of imprinting in other iPSC models is similarly
misregulated in our cell lines, although the significance of this phenotype is unclear.
Importantly, both models overcome issues related to mosaicism: the mouse
model displays full penetrance of the epigenetic/genetic phenotype, and the iPSC lines
are clonally-driven. Moreover, cell types of interest are readily accessible/can be derived
from both models. Therefore, the work in this thesis emphasizes the utility of both
mouse/human as well as in vivo and in vitro complementary approaches in studying
imprinting mechanisms.
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Figure 1.1 Genomic imprinting. Majority of the mammalian genes (purple boxes) are expressed
from both parental alleles. However, imprinted genes (red and blue boxes) are expressed in a
monoallelic, parent-of-origin specific manner. The blue box represents a paternally expressed
imprinted gene, and the red box represents a maternally expressed imprinted gene. Expression is
indicated by arrow, and silenced genes are illustrated in grey boxes. The parent-of-origin of the
allele is indicated with a female(♀) or a male (♂) symbol on the left.
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Figure 1.2 DNA methylation reprogramming at ICRs. The figure illustrates a scheme for a
paternally methylated ICR (yellow box). During germ cell development, sex-specific DNA
methylation pattern (filled lollipops represent methylated CpGs; empty lollipops represent
unmethylated CpGs) is established at the ICR. Following fertilization, the parental-allele specific
ICR methylation is maintained in somatic cells; the parent-of-origin of the ICR is indicated with a
female(♀) or a male (♂) symbol next to the ICR in diploid nuclei. In the primordial germ cells
(PGCs) of a growing embryo, somatic methylation pattern is erased, allowing re-establishment of
a sperm- or oocyte-specific methylation at the ICR. The figure is adapted from Weaver et al.
(Weaver et al., 2009)
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Figure 1.3 Insulator model of imprinting at the H19/Igf2 locus in mouse. On the maternal
allele (♀), CTCF binds to the unmethylated IC1, Igf2 expression is blocked, and H19 is expressed.
On the paternal allele (♂), the IC1 is methylated, CTCF does not bind, Igf2 is free to interact with
the downstream enhancers and is expressed; H19 is silenced due to methylation at its promoter.
Centromeric (C) and telomeric (T) ends are indicated. Not drawn to scale.
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Figure 1.4 LncRNA model of imprinting at the Cdkn1c/Kcnq1ot1 locus in mouse. On the
maternal allele (♀), Kcnq1ot1 is not expressed due to methylated IC2; thus, adjacent imprinted
genes are expressed. On the paternal allele (♂), unmethylated IC2 allows the expression of
Kcnq1ot1; Kcnq1ot1 silences genes in cis bidirectionally. Only imprinted genes are labeled.
Centromeric (C) and telomeric (T) ends are indicated. Not drawn to scale.
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Figure 1.5 H19 and miR-675 in therians. (A) Scale illustration of H19 gene in eutherians
(human and mouse) and marsupials (wallaby and opossum). Although sequence conservation
between eutherians and marsupials is low, the exonal structure of the gene is largely conserved
in therians. Each exon (E) is depicted in red box. The conserved miR-675 sequence is
represented in pink box within E1. (B) Shown is the precursor regions of the conserved miR-675
in human and mouse. The predicted mature forms of the miR-675-5p and the miR-675-3p are
underlined. Figures adapted from Smits et al. (Smits et al., 2008).
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Figure 1.6 Alterations associated with BWS and SRS. In both pie charts, alterations found in
human 11p15 are represented in colored slices. UPD11: uniparental isodisomy of chromosome
11; UPD7: uniparental isodisomy of chromosome 7 (Ishida, 2016; Soejima and Higashimoto,
2013; Weksberg et al., 2010).
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Figure 1.7 IC1 microdeletions and OCT4-binding site point mutations found in BWS IC1
hypermethylation cases. Examples of previously reported mutations at the locus. Here, human
IC1 that has seven CTCF binding site (CTS) is illustrated; CTSs within IC1 are numbered for
convenience. IC1 microdeletions are depicted in red lines; deletion length and CTS removed by
the microdeletion are indicated next to each red line. OCT4-binding sites (Oct4 motif: OM) are
noted with inverted triangles; within OM2, three octamer binding motifs are underlined; point
mutations are indicated with arrows. Figure modified from Ideraabdullah et al. and Beygo et al.
(Beygo et al., 2013; Demars et al., 2010; Habib et al., 2014; Ideraabdullah et al., 2008; Poole et
al., 2012; Prawitt et al., 2005; Sparago et al., 2004).
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Figure 1.8 pUPD11. A schematic of the 11p15 imprinted loci in non-pUPD11 (top) and pUPD11
(bottom). Cdkn1c/Kcnq1ot1 locus, regulated by the maternally methylated IC2, is depicted on the
left, and H19/Igf2 locus, regulated by the paternally methylated IC1, is depicted on the right. For
simplicity, only selected imprinted genes are shown for the Cdkn1c/Kcnq1ot1 locus. pUPD11
cells have two copies of paternal allele in this region. The parent-of-origin of the allele is indicated
with a female(♀) or a male (♂) symbol. Centromeric (C) and telomeric (T) ends are indicated. Not
drawn to scale.
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CHAPTER 2.
HUMANIZED MOUSE MODEL
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2.1 Background and study rationale
Comparative genome studies have revealed extensive conservation of H19/Igf2
in therians (Smits et al., 2008). Consistently, key features of imprinting, as well as spatial
organization of the mouse and human loci, are shared, including DNA methylation
patterns, presence of CTSs at IC1, and downstream enhancers. Notably, however, the
length of IC1 and the number of CTSs within IC1 have diverged; the ∼5-kb human IC1
has seven CTSs, whereas the corresponding mouse sequence is ∼2 kb and has four
CTSs (Figure 2.1). In addition, with the exception of the CTCF-binding motifs, IC1
exhibits low sequence homology between mouse and human (Jinno et al., 1996; Jones
et al., 2002). This raises the question of whether the human IC1 sequence could
successfully regulate H19/Igf2 imprinting in the mouse. If it can, then an in vivo model for
imprinting disorders associated with mutations at human IC1 could be generated (Figure
1.7).
Although interspecies compatibility of human IC1 was previously investigated in a
transgenic mouse model (Jones et al., 2002), the human transgene failed to exhibit the
expected imprinting pattern. The transgene acquired DNA methylation in male germ
cells in a copy number-dependent manner, but the methylation was not stably
maintained in somatic cells. In addition, the human H19 transgene was abnormally
expressed on paternal transmission. Interpretation of these observations is complicated
by transgene copy number variation, however. Furthermore, because long-range
chromatin looping plays an essential role in H19/Igf2 imprinting (Engel et al., 2008;
Nativio et al., 2011), the transgene insertion site may influence the phenotype. Thus, it is
imperative to test the functionality of the human IC1 element at the orthologous locus.
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Here we generated a knock-in mouse model in which the endogenous mouse
IC1 (mIC1) was replaced by human IC1 (hIC1). Our goal was to investigate the extent to
which hIC1 can functionally replace mIC1. We found that hIC1 properly recapitulates
mIC1 function on the maternal allele, whereas hIC1 fails to properly regulate the
H19/Igf2 locus on the paternal allele. hIC1 is incompletely methylated in the male germ
cells of knock-in mice, which is associated with increased enrichment of H3K4me2 at
hIC1. Overall, this study reveals interspecies incompatibility of hIC1 in the mouse male
germline. Importantly, we show that abnormal histone modification composition at hIC1
may affect the proper establishment of DNA methylation at hIC1 during mouse germ cell
development.
2.2 Generation of the H19hIC1 allele
To determine whether hIC1 could functionally substitute for the orthologous
mouse sequence, we replaced the endogenous mIC1 with hIC1 by gene targeting in
ESCs (Figure 2.2A). Even though we obtained highly chimeric mice after blastocyst
injection of the targeted ESCs, germline transmission of the targeted allele was
inefficient. Only one female pup with the H19hIC1 allele was live-born out of >250 agouti
pups; all other agouti pups were wild-type, suggesting that the pups inheriting the
H19hIC1 allele might be dying prenatally. The single live-born female knock-in pup was of
noticeably smaller size compared with its wild-type siblings and remained small. The
neomycin resistance cassette (NeoR) was excised by crossing the female to EIIA-Cre
male on a C57BL/6J (B6) background (Jackson Laboratories). Germ-line transmission of
the targeted allele and excision of NeoR were confirmed by Southern blot analysis
(Figure 2.2B). When bred to a B6 male, the female knock-in mouse was fertile, and wildtype and knock-in progeny were born in the expected Mendelian ratios with no sex bias.
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Embryonic lethality on paternal transmission was again observed after NeoR excision.
The use of knock-in males in a B6/CF1 mixed strain for paternal transmission did not
resolve the embryonic lethality. These results rule out NeoR and pure B6 background as
being solely responsible for the failure to obtain mutant pups. The H19hIC1 allele was
maintained through maternal transmission in a B6 background.
2.3 IC1 imprinting upon maternal transmission of the H19hIC1 allele
To investigate H19 and Igf2 imprinting when the targeted allele was maternally
transmitted, we bred female H19hIC1/+ mice to B6 (CAST7) mice, which have a Mus
musculus castaneus chromosome 7 on a B6 background (Mann et al., 2003). This cross
allows the parental origin of H19 and Igf2 expression to be distinguished in F1 progeny.
Heterozygous H19hIC1/+ mice were compared with their wild-type littermates (H19+/+). The
H19hIC1/+ and H19+/+ mice were born in Mendelian ratios with no sex bias and no
difference in neonatal weight (Figure 2.3A). We assayed expression and IC1 methylation
in neonatal livers, where H19 and Igf2 are highly expressed, and detected monoallelic
expression in all cases (Figure 2.3B). Consistently, total expression levels of H19 and
Igf2 were statistically equivalent in H19+/+ and H19hIC1/+ livers, as measured by
quantitative real-time PCR (qRT-PCR) (Figure 2.3C). DNA methylation at hIC1 on the
maternal allele and endogenous mIC1 on the paternal allele was measured by bisulfite
mutagenesis of genomic DNA, followed by pyrosequencing. The maternal hICI was
hypomethylated, as expected (Figure 2.4A). Methylation at several other ICRs in
H19hIC1/+ livers was normal, suggesting that the general imprinting machinery is
functioning normally (Figure 2.4B). Finally, hIC1 was properly hypomethylated in the
oocytes of H19hIC1/+ females (Figure 2.4C). We repeated these analyses in two
sequential generations of the H19hIC1 allele maternal transmission offspring and obtained
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the same results. Overall, these data illustrate that hIC1 can functionally replace mIC1
on the maternal allele.
2.4 IC1 imprinting upon paternal transmission of the H19hIC1 allele
To investigate H19 and Igf2 imprinting on the paternal allele, we bred male
H19hIC1/+ mice to B6 (CAST7) mice. All live-born neonates were wild-type, similar to
what was observed when breeding for germ-line transmission in chimeric mice,
suggesting that paternal transmission of the H19hIC1 allele is embryonic lethal. To
investigate this possibility, we isolated E15.5 conceptuses. Although the H19+/hIC1
conceptuses were viable, the H19+/hIC1 embryos and placentas were smaller and
weighed significantly less compared with those of H19+/+ (Figure 2.5A). Anecdotally,
such a size difference was not apparent at E10.5, and a trend toward a smaller size was
observed at E12.5. The fetal/placental weight ratio was not different between E15.5
H19+/+ and H19+/hIC1, demonstrating that H19+/hIC1 tissues were proportionately smaller
(Figure 2.5B). Allele-specific RNA analysis revealed biallelic H19 in E15.5 H19+/hIC1 livers
and placentas, with equal expression derived from the two parental alleles (Figure 2.5C
and E), suggesting complete derepression of paternal H19. In contrast, paternal Igf2
expression was barely detectable, indicating complete repression of Igf2 (Figure 2.5C
and E). Consistently, qRT-PCR analyses revealed approximately 3.4-fold and 1.5-fold
increases of H19 in liver and placenta, respectively, and undetectable Igf2 in H19+/hIC1
compared with H19+/+ embryos in both tissues (Figure 2.5D and F). Similar results were
observed in E9.5 whole embryos (Figure 2.5G and H).
We next examined the extent to which methylation at hIC1 correlated with
abnormal expression in heterozygous livers and placentas. hIC1 was completely
unmethylated on the paternal allele, resembling the endogenous mIC1 on the maternal
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allele (Figure 2.6A and B). This unusual methylation pattern was not due to a gross
defect in the methylation machinery, because methylation at other ICRs was normal in
H19+/hIC1 embryos (Figure 2.6C).
Finally, to determine whether the hypomethylated state of hIC1 is associated with
ectopic binding of CTCF on the paternal allele, we performed allele-specific chromatin
immunoprecipitation (ChIP) followed by quantitative real-time PCR (ChIP–qRT-PCR) for
CTCF in E12.5 mouse embryonic fibroblasts (MEFs). As expected, CTCF bound only to
the unmethylated hIC1 on the maternal allele and did not bind to the methylated mIC1
on the paternal allele in H19hIC1/+ MEFs. In contrast, CTCF bound to both the
unmethylated mIC1 on the maternal allele and the unmethylated hIC1 on the paternal
allele in H19+/hIC1 MEFs (Figure 2.7). The results demonstrate that paternal hIC1 is
unable to acquire or maintain the hypermethylated state of endogenous mIC1, fails to
repress H19, and instead gains a CTCF-dependent insulator function.
Because the paternal allele in E15.5 H19+/hIC1 embryos was hypomethylated, we
assayed DNA methylation at earlier stages. We did not detect any methylation at hIC1
as early as the blastocyst stage (Figure 2.8).
2.5 DNA methylation at the H19hIC1 allele in the male germline
The observation that hIC1 was hypomethylated even as early in the blastocyst
stage embryos suggested that either methylation was not established during
spermatogenesis or methylation was established but was lost during preimplantation
development. To distinguish between these possibilities, we examined DNA methylation
at hIC1 in sperm of H19hIC1/+ males, and observed partial methylation (Figure 2.9A and
B). As positive controls, we analyzed methylation at endogenous hIC1 in human sperm
samples from two fertile men as well as at endogenous mIC1 in H19hIC1/+ sperm and
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found that all were hypermethylated, as expected (Figure 2.9A and B). To explore
whether the methylation at hIC1 in H19hIC1/+ sperm could be maintained after the first
cleavage division, we assayed H19+/hIC1 two-cell embryos in which the zygote had
undergone one round of mitosis. We found reduced methylation levels (close to one-half
less) at hIC1 in two-cell embryos compared with mature sperm (Figure 2.9A). These
results demonstrate that the DNA methylation is partially established at hIC1 during
spermatogenesis, but is not maintained in preimplantation development.
2.6 Histone modification at the H19hIC1 allele in the male germline
To investigate factors that may inhibit complete establishment of DNA
methylation at hIC1 during spermatogenesis, we examined histone modifications at hIC1.
Parental allele-specific histone modifications have been described at mIC1 in both
somatic and germ cells (Delaval et al., 2007; Lee et al., 2010; Singh et al., 2013; Stewart
et al., 2015; Verona et al., 2008). For instance, H3K4 methylation is found preferentially
on the hypomethylated maternal IC1, and H3K9me3 is found on the hypermethylated
paternal IC1 in mouse and human somatic cells (Delaval et al., 2007; Nativio et al.,
2011)). The antagonistic relationship between “activating marks” and DNA methylation
(Ciccone et al., 2009; Ooi et al., 2007; Singh et al., 2013; Stewart et al., 2015) has been
well-established. Moreover, several studies illustrated a strong relationship between
“repressive marks,” such as H3K9me3 and DNA methylation (Rose and Klose, 2014).
Therefore, we hypothesized that depletion of H3K9me3, increased enrichment of
H3K4me2, or both contribute to the inability to fully establish DNA methylation at hIC1.
Spermatogenic cells were fractionated by the STA-PUT method, and chromatin was
isolated from a round spermatid-enriched fraction (Bryant et al., 2013). ChIP–qRT-PCR
analyses in round spermatids revealed that hIC1 had fivefold greater enrichment of
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H3K4me2 compared with mIC1 (Figure 2.9C). Unlike previous studies that did not report
significant enrichment of H3K9me3 above background at mIC1 in the male germ line
(Delaval et al., 2007; Singh et al., 2013), we obtained a ChIP signal above background.
This discrepancy could be attributed to the different antisera used for H3K9me3.
Nevertheless, there was no difference in the enrichment of H3K9me3 between hIC1 and
mIC1. Our finding that the difference in H3K4me2 between mIC1 and hIC1 is greater
than the difference in H3K9me3 suggests that (i) H3K9me3 does not affect the
acquisition of DNA methylation at hIC1 during spermatogenesis, and (ii) enrichment of
activating histone marks at hIC1 contributes in part to the incomplete establishment of
imprinting at hIC1 during spermatogenesis (Figure 2.9C).
2.7 Additional analyses upon paternal transmission of the H19hIC1 allele
Because H19+/hIC1 embryos display similar phenotypes to many SRS patients that
present with IC1 hypomethylation including altered H19 and Igf2 expression and growth
defects (Gicquel et al., 2005; Yamazawa et al., 2008), we hypothesized that these
embryos can serve as a model for SRS. Thus, we further characterized H19+/hIC1
embryos and placentas to study potential mechanisms underlying SRS associated with
IC1 hypomethylation.
2.7.1 Imprinted gene network (IGN) genes in H19+/hIC1
We first investigated several IGN genes, focusing on seven genes (maternally
expressed Cdkn1c, Gtl2, Igf2r, and paternally expressed Dlk1, Gnas, Peg3, Slc38a4)
whose levels were previously shown to be affected by H19 expression in trans (Gabory
et al., 2009). In H19+/hIC1 livers, three of the four paternally expressed genes (Dlk1, Gnas,
Slc38a4) were significantly upregulated, whereas in H19+/hIC1 placentas, two of the three
maternally expressed genes (Cdkn1c, Gtl2) were downregulated compared to H19+/+,
42

suggesting tissue-specific regulation of IGN genes (Figure 2.10). The changes were
more subtle in placentas compared to livers. Overall, these results support the
previously proposed homeostatic role of IGN genes in controlling fetal growth.
2.7.2 Placental morphology in H19+/hIC1
Placental growth defects are prevalent among SRS individuals (Yamazawa et al.,
2008). Thus, we performed histological analyses on E15.5 H19+/hIC1 placentas to explore
whether abnormal placentation could contribute to embryonic growth restriction, given
that H19 and Igf2 play essential roles in placental development (Bartolomei and
Ferguson-Smith, 2011; Reik et al., 2003). In addition to being smaller (~74% of H19+/+),
H19+/hIC1 placentas displayed an increased junctional to labyrinthine zone ratio, indicative
of abnormal placenta morphology (Figure 2.11A and B).
2.7.3 miR-675 in H19+/hIC1
Lastly, miR-675 was analyzed in the H19+/hIC1 embryos and placentas. The role of
miR-675 in limiting cell proliferation has been demonstrated in various cell types in vitro
(Keniry et al., 2012). Thus, we measured the level of miR-675-3p and miR-675-5p in
E15.5 H19+/hIC1 livers and placentas. Despite being more highly expressed in placentas
compared to livers, both miR-675-3p and miR-675-5p were elevated only in H19+/hIC1
livers but not in placentas compared to H19+/+ (Figure 2.12A). These data suggest that in
addition to greatly reduced Igf2 and increased H19 expression in H19+/hIC1 placentas and
embryos, increased miR-675 expression in embryos may further restrict the growth of
embryos.
Keniry et al. proposed Igf1r as a potential target of miR-675-3p (Keniry et al.,
2012). To support this idea, Igf1r is upregulated in E18.5 mouse placenta in which H19
sequence is deleted (Keniry et al., 2012), suggesting that the concurrently deleted miR43

675 could be repressing Igf1r. Thus, we expected that in H19+/hIC1 livers, where miR-675
is upregulated, Igf1r would be downregulated. Contrary to our hypothesis, Igf1r was
upregulated in H19+/hIC1 livers. In placentas, Igf1r level was unchanged, consistent with
no significant change in miR-675 expression in this tissue (Figure 2.12B). These data
suggest that the miR-675 mediated silencing of Igf1r does not occur in liver or that other
dominant molecular phenotypes caused by IC1 hypomethylation might be masking the
silencing effect of miR-675.
2.8 Testing the role of miR-675 vs H19 in growth regulation
Potentially distinct mechanisms used by H19 and miR-675 to suppress
embryonic growth have not been investigated in a tissue-and/or temporal-specific
manner. To address this, the H19+/hIC1 animals that exhibit increased H19 and miR-675
expression and severe growth phenotype could serve as an informative platform (Figure
2.13A). Therefore, we have designed two rescue experiments that would allow us to test
the role of miR-675 independent of H19 in growth restriction caused by IC1
hypomethylation (Figure 2.13B and C). This approach could shed light on the
contribution of miR-675 and H19 in the etiology of SRS.
2.8.1 H19+/miR-675mut x H19hIC1/+
H19miR-675mut allele
First rescue experiment utilizes the mouse model, designated H19miR-675mut,
generated by a previous member of the Bartolomei lab, Jennifer Kalish, MD, PhD. In this
mouse model, the miR-675 sequence was mutated such that the stem-loop structure of
the miR is maintained while the targeting ability is impaired. This mouse model does not
seem to have any apparent phenotype thus far (personal communication with Jennifer
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Kalish). Importantly, H19 expression is not affected in this model (Kalish et al.,
unpublished).
Mating scheme
The goal is to generate offspring from H19+/miR-675mut females and H19hIC1/+ males
(Figure 2.13B). This will allow us to analyze the extent to which the reduced dosage of
miR-675 has an effect in relieving the molecular and/or physiological phenotypes of the
H19+/hIC1 animals. Thus, we will be able to elucidate the contribution of miR-675 in
leading to the SRS-like phenotypes. These crosses have been setup and the E15.5 and
E18.5 embryos and placentas will be collected.
2.8.2 H19+/△H19 x H19hIC1/+
Generation of the H19△H19 allele
As a complementary approach, we generated a mouse model, designated
H19△H19, in which the H19 sequence is deleted using the Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology. To do this, two
different pairs (pair A and B) of guide RNA (gRNA) were designed using the program
developed by the laboratory of Dr. Feng Zhang (http://www.genomeengineering.org/crispr/?page); within a pair of gRNA, each gRNA was designed to target
the 5’ or the 3’ end of the H19 sequence (Figure 2.14A). The gRNAs were in vitrotranscribed and injected with Cas9 mRNA (Trilink) directly into zygote stage embryos in
B6 background. One pair of gRNA (either pair A or pair B) was injected per embryo. This
approach led to in total ~26% efficiency in generating both female and male chimeras,
with pair B exhibiting a higher efficiency (~24%) than pair A (~2%). Sequencing the
deleted region revealed 2.7kb to 2.8kb deletion in the chimeras (Figure 2.14B). The
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chimeras successfully transmitted the mutant allele through the germline. Both female
and male mutant mice were fertile, and wild-type and mutant progeny were born in the
expected Mendelian ratios with no sex bias. The mutant allele is currently maintained in
B6 background via paternal transmission.
Previous mouse models deleting the H19 sequence (Leighton et al., 1995b;
Ripoche et al., 1997) left a transcription unit at the deleted site— NeoR cassette—that
could potentially interfere with the imprinting mechanism at the locus. The other H19deletion mouse (Schmidt et al., 1999) left a loxP site at the locus. Importantly, the
H19△H19 allele we generated does not introduce any exogenous sequence at the locus,
eliminating the possibility of imprinting regulation being affected.
Characterization of the H19+/△H19 and the H19△H19/+ animals
Day 0 neonatal weight was analyzed in the maternal transmission (H19△H19/+) and
the paternal transmission (H19+/△H19) animals. There was no significant weight difference
between H19+/△H19 compared to wild-type siblings (H19+/+) (Figure 2.15A); yet, H19△H19/+
were significantly heavier compared to H19+/+ (i.e. H19△H19/+ displayed on average 13.8%
increase in body weight compared to H19+/+) (Figure 2.15B). This result is similar to the
observation made in the previous H19-deletion mouse models, where they noticed 412% increase in body weight in day 3-5 neonates in various genetic backgrounds
(Ripoche et al., 1997; Schmidt et al., 1999). Thus, our mouse model supports the role of
H19 being a maternally expressed growth suppressor.
Nevertheless, molecular analyses of these mice remain to be completed. Various
tissues of the neonates were collected including brain, tongue, liver, kidney, and heart.
Select tissues will be analyzed for parameters including allele-specific and total
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expression of H19 and Igf2 and DNA methylation at IC1 to address the necessity of H19
in the maintenance of imprinting at the H19/Igf2 locus. In addition, germ cells of these
mice will be analyzed to address the effect of H19 deletion in methylation establishment
at the IC1.
Mating scheme
Similar to the approach proposed for the H19miR-675mut allele, the goal is to
generate offspring from H19+/△H19 females and H19hIC1/+ males (Figure 2.13C). These
crosses have been setup and the E15.5 and E18.5 embryos and placentas will be
collected. This strategy will address the extent to which reducing the dosage of both H19
and miR-675 alters the SRS-like phenotypes in the H19+/hIC1 animals.
2.9 Discussion
Using a mouse model replacing endogenous mIC1 with hIC1, we show that the
ability of hIC1 to functionally replace mIC1 depends upon the parental origin of the hIC1
allele.
Maternally transmitted hIC1 properly carries out imprinting regulation at the
endogenous mouse locus, suggesting that the IC1 imprinting on the maternal allele is
largely conserved between mouse and human (Figure 2.16). Paternal transmission of
hIC1, in contrast, leads to loss of H19 and Igf2 imprinting; H19 displays biallelic and
increased expression and Igf2 is silenced (Figure 2.17). Offspring inheriting hIC1
paternally also exhibit severe growth restriction. Other studies have shown that Igf2 null
neonates are born smaller but viable (Baker et al., 1993; DeChiara et al., 1990),
suggesting that prenatal lethality of H19+/hIC1 is not solely due to loss of Igf2. Notably,
ectopic expression of H19 caused late-gestation lethality (Brunkow and Tilghman, 1991).
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Thus, changes in both H19 and Igf2 may synergistically contribute to the severe growth
restriction and prenatal lethality of H19+/hIC1.
In addition to changes in H19 and Igf2, miR-675 and IGN gene levels are altered
in H19+/hIC1 embryos and placentas (Figure 2.17). To our knowledge, this is the first
report showing that complete biallelic insulation at the endogenous H19/Igf2 locus could
lead to changes in miR-675 or other growth-regulating imprinted genes in vivo. Given
that the maternally expressed imprinted genes tend to suppress growth, whereas
paternally expressed imprinted genes promote growth, the seemingly disparate changes
in IGN gene expression between H19+/hIC1 livers and placentas both encourage growth.
This result reaffirms the previously proposed homeostatic role of IGN genes to control
embryonic and placental growth. Despite these potentially compensatory changes,
however, H19+/hIC1 embryos are still severely growth-restricted and die prenatally.
Whether the increased level of miR-675 or H19 in H19+/hIC1 liver contributes to the
embryonic growth restriction phenotype needs to be further investigated. We have setup
experiments to specifically address this question as discussed in Chapter 2.8.1 and
2.8.2. Surprisingly, miR-675 is only increased in livers, but not in placentas. It will be
interesting to assess the expression of miR-675 later in gestation, such as E18.5-19.5,
when the highest level of miR-675 is observed in both liver and placenta (Keniry et al.,
2012). However, it is possible that miR-675 is differently regulated in liver compared to
placenta.
The upregulation of Igf1r transcript, observed in a tissue where miR-675 was
upregulated, is unexpected. This result does not invalidate Igf1r as a potential target of
miR-675 in placenta (Keniry et al., 2012). Nevertheless, it is possible that the miR-675
regulation of Igf1r is cell-type specific. Given that H19+/hIC1 tissues display changes in the
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expression of Igf2 and other IGN genes, upregulation of the Igf1r transcript perhaps
reflects a response to the altered IGF2-associated signaling pathway.
Previous studies illustrated that abnormal H19 and Igf2 expression is linked to
both placental and embryonic growth defects. Deletion of a placenta-specific Igf2
transcript resulted in growth restriction of embryos in late gestation (Constância et al.,
2002). In a mouse model in which H19 is deleted and Igf2 expression is increased, both
placenta and fetus are overgrown at E19 (Angiolini et al., 2011; Leighton et al., 1995b).
In humans, placental growth defects are common among individuals with BWS and SRS
(Armes et al., 2012; Yamazawa et al., 2008). We observed that H19+/hIC1 placentas are
not only smaller but have abnormal placental morphology. While the contribution of an
abnormal placenta to fetal growth defects is unclear, it is noteworthy that H19 is more
highly expressed in labyrinthine zone compared to junctional zone (Keniry et al., 2012),
and that Igf2 null mice display a disproportionate reduction of labyrinthine zone
compared to junctional zone (Coan et al., 2008). These observations suggest a potential
major growth-suppressing effect of increased H19 and silenced Igf2 expression in the
labyrinthine zone.
We also show that hIC1 is partially methylated in the male germline of H19hIC1/+
mice. This phenotype contrasts that of other mouse models that carry mIC1 mutations;
in these mice, methylation is properly established at non-mutated CpGs in the male
germline (Engel et al., 2004, 2006). This result suggests that interspecies
communication between mouse and human in establishing IC1 methylation is ineffective.
Based on our finding that hIC1 is abnormally enriched with activating H3K4me2 marks in
the male germ cells, it is tempting to speculate that somatic histone modification marks
carried from the maternal allele are not completely erased in the male germ cells (note
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that hIC1 was necessarily transmitted maternally to generate offspring). Consequently,
the establishment of DNA methylation at hIC1 is inhibited. This finding adds to the
growing consensus that H3K4 methylation marks are inhibitory to de novo DNA
methylation in the germline, whereas repressive histone marks do not play major role in
methylation establishment at ICRs (Ciccone et al., 2009; Delaval et al., 2007; Lee et al.,
2010; Singh et al., 2013; Stewart et al., 2015).
Finally, we show that the partially established methylation at hIC1 in the male
germline is not properly maintained during preimplantation development. We also
illustrate that CTCF ectopically binds to the hIC1 on the paternal allele in somatic cells.
Similar results are described in a previous mouse model in which CpGs within the CTCF
binding sites at the mIC1 were mutated to abrogate methylation, while retaining the
CTCF-binding motifs intact. There, although methylation was properly established in the
male germ cells at the mIC1, it was not maintained during preimplantation development
(Engel et al., 2004). These data suggest that CTCF binding inhibits maintenance of DNA
methylation in somatic cells, although the mechanism remains unknown. Alternatively,
hIC1 might lack properties that allow the mouse imprint maintenance machinery to
properly recognize the sequence. It is also possible that hIC1 contains inhibitory signals
that block accessibility and/or activity of the mouse imprint maintenance machinery.
2.10 Contributions
This chapter contains direct quotes and figures from Hur et al. published in 2016
in Proceedings of the National Academy of Sciences (PNAS) (Hur et al., 2016). The
target vector for the H19hIC1 mouse was made by a collaborative effort between Dr.
Folami Ideraabdullah, a former member of the lab, currently at the University of North
Carolina at Chapel Hill, and Andrea Freschi, currently in the laboratory of Dr. Andrea
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Riccio at the Second University of Naples, Italy. Members of the laboratory of Dr. Shelley
Berger at the time, including Dr. Lacey Luense and Ms. Angela Hines, performed the
STA-PUT experiments. Dr. Catherine May in the laboratory of Dr. Klaus Kaestner
provided guidance in generating the H19△H19 allele using the CRISPR/Cas9 technology.
Dr. Joanne Thorvaldsen provided advice and guidance in performing experiments.
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Figure 2.1 Comparison between mouse and human IC1. Mouse IC1 (top) has four CTSs and
is ~2kb long. Human IC1 (bottom) has seven CTSs and is ~5kb long. Except for the CTCFbinding motifs, overall sequence homology between the two IC1 is low (Jinno et al., 1996; Jones
et al., 2002). The number of CpG sites and CpG density at IC1 are noted in the table.
Approximate distance between H19 and IGF2 in both mouse and human are indicated. CTSs are
numbered for convenience. Human and mouse drawings were adapted from Renfree et al.
(Renfree et al., 2013).
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Figure 2.2 Targeting strategy to generate the H19hIC1 allele. (A) Schematics of the
endogenous locus, targeting vector (phIC1-neo), correctly targeted allele (H19hIC1-neo), and
targeted allele after excision of the neoR cassette (H19hIC1). Depicted are the IC1 (white
rectangle) with CTCF binding sites (black blocks within the IC1), H19 exons (gray rectangles),
pBluescriptIIKS sequence (bold line), neoR cassettes (green rectangles), loxP sites (black
arrowheads), and endogenous mouse DNA (thin line). Restriction sites and their relative positions
(in kb) to the H19 transcription start sites are indicated above the endogenous locus. Probes (A,
B, and C) used for Southern blot analyses are shown as thick lines below the endogenous locus.
(B) Southern blot analysis to confirm correct targeting of the alleles. Genomic DNA from the wildtype mouse (+/+), knock-in mouse before neoR excision (hIC1-neo/+), and knock-in mouse after
neoR excision (hIC1/+) was either digested with EcoRV-MluI and hybridized to external 5’probe A
or digested with StuI and hybridized to external 3’probe B or to internal probe C. (C) Depiction of
mIC1 (top) and hIC1 (bottom) highlighting PCR analyzed regions (a-m). IC1s are illustrated in the
orientation shown in Fig 2.2A, with each CTCF binding site (CTS) numbered. a: bisulfite
treatment followed by sequencing for mIC1; b,c: chromatin immunoprecipitation followed by
quantitative real-time PCR (ChIP-qRT-PCR) for mIC1; d: pyrosequencing for mIC1; e-h: bisulfite
treatment followed by sequencing for hIC1; i-k: ChIP-qRT-PCR for hIC1; l: pyrosequencing for
hIC1; m: bisulfite treatment followed by sequencing for hIC1 (used for oocytes).
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Figure 2.3 Weight and expression analyses of maternal transmission of the H19hIC1 allele.
(A) Neonatal (P0) weight of wildtype (+/+) and heterozygous (hIC1/+) mutant offspring. (B) Allelespecific expression of H19 and Igf2 in neonatal liver analyzed by restriction fragment length
polymorphism (RFLP). Genotypes (+/+ and hIC1/+) and maternal (m) and paternal (p) allele
controls are indicated above each gel. (C) Total expression of H19 and Igf2 in neonatal liver
analyzed by qRT-PCR. (A,C) Two-tailed Student's T-test with equal variance; no significant
differences were observed. (A-C) +/+: n=11, hIC1/+: n=12 (from three litters). Bars represent the
mean ± SEM; error bars in (A) are too small to be seen on the graph.
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Figure 2.4 Methylation analyses of maternal transmission of the H19hIC1 allele. (A) Percent
methylation at IC1 in neonatal liver measured by pyrosequencing. Maternal (m) and paternal (p)
alleles in hIC1/+ are shown separately as different primers were used; assay d was used for the
+/+ and hIC1/+(p); assay l was used for the hIC1/+(m) (Figure 2.2C). (B) Methylation levels of
Kcnq1ot1, Peg1, Peg3, Snrpn, Dlk1/Gtl2 (IG-DMR) ICRs were measured by pyrosequencing in
neonatal liver. (C) IC1 methylation in oocytes analyzed by bisulfite treatment followed by
sequencing. Assay a was used for mIC1; assay m was used for hIC1 (Figure 2.2C). Empty and
filled circles indicate unmethylated and methylated cytosines in CG dinucleotides, respectively.
Each horizontal row of circles denotes individual strands of cloned DNA. Cytosines in CG
dinucleotides that are conserved between mouse and human and located within CTS are
depicted as black lines above the clones and marked as CTS 2 and 6 (Bell and Felsenfeld, 2000).
(A,B) +/+: n=11, hIC1/+: n=12 (from three litters). (B) Two-tailed Student's T-test with equal
variance; no significant differences were observed. Bars represent the mean ± SEM; error bars in
(A) and (B) are too small to be seen on the graph.
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Figure 2.5 Weight and expression analyses of paternal transmission of the H19hIC1 allele.
(A) E15.5 fetal and placental weight of wild-type (+/+) and heterozygous (+/hIC1) mutant offspring.
(B) Fetal/placental weight ratio of E15.5 samples. Allele-specific expression of H19 and Igf2 in (C)
E15.5 liver, (E) E15.5 placenta, and (G) E9.5 whole embryo analyzed by RFLP. PCR cycle
numbers varied between +/+ and +/hIC1 for Igf2 (see Table 5.1). Total expression of H19 and
Igf2 in (D) E15.5 liver, (F) E15.5 placenta, and (H) E9.5 whole embryo analyzed by qRT-PCR.
Two-tailed Student's T-test with (A) equal variance and (D,F,H) unequal variance; ** (P < 0.01);
*** (P < 0.001); **** (P < 0.0001). (A,B,D,F) +/+: n=8, +/hIC1: n=6 (from two litters). (H) +/+: n=5,
+/hIC1: n=7 (from two litters). Bars represent the mean ± SEM; error bars in (D,F,H) are too small
to be seen on the graph.
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Figure 2.6 Methylation analyses of paternal transmission of the H19hIC1 allele. Percent
methylation at IC1 in (A) E15.5 liver and (B) E15.5 placenta measured by pyrosequencing; assay
d was used for the +/+ and +/hIC1(m); assay l was used for the +/hIC1(p) (Figure 2.2C). (C)
Methylation levels of Kcnq1ot1, Peg1, Peg3, Snrpn, Dlk1/Gtl2 (IG-DMR) ICRs were measured by
pyrosequencing in E15.5 liver. (A,B,C) +/+: n=8, +/hIC1: n=6 (from two litters). Error bars in (A-C)
are too small to be seen on the graph. (C) Two-tailed Student's T-test with equal variance; no
significant differences were observed. Bars represent the mean ± SEM. (A,B,C) error bars are too
small to be seen on the graph.
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Figure 2.7 CTCF-binding analyses of paternal transmission of the H19hIC1 allele. CTCF
binding at mIC1 and hIC1 in heterozygous (hIC1/+ and +/hIC1) E12.5 MEFs analyzed by ChIPqRT-PCR; assays b, c, i, k were used (Figure 2.2C); results from two biological replicates are
shown separately; y-axis denotes percent input of CTCF IP normalized to non-specific IgG
(percent input CTCF - percent input IgG).
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Figure 2.8 Methylation at IC1 in H19+/hIC1 embryos during development. Bar graphs
summarize the DNA methylation status of E9.5 whole embryo (+/+: n=5, +/hIC1: n=7, two litters),
E6.5 whole embryo (+/+: n=5, +/hIC1: n=7, two litters), and blastocysts (+/+: n=6, +/hIC1: n=9,
four litters) measured by pyrosequencing. Assay d was used for the +/+ and +/hIC1(m) and assay
l was used for the +/hIC1(p) (Figure 2.2C). On the right, methylation at hIC1 was analyzed by
bisulfite treatment followed by sequencing in one representative +/hIC1 sample from each
developmental stage; assays e-h were used (Figure 2.2C). Cytosines in CG dinucleotides that
are conserved between mouse and human and located within CTS are depicted as black lines
above the clones and marked as CTS 1,2,3,4, and 6 (Bell and Felsenfeld, 2000). Cytosines
measured by pyrosequencing are marked with an asterisk. Bars represent the mean ± SEM.
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Figure 2.9 Incomplete establishment of imprinting at the hIC1 in knock-in male germ cells.
(A) Percent methylation at IC1 measured by pyrosequencing; assays d and l were used (Figure
2.2C). From left to right, results at the endogenous hIC1 in mature sperm samples from fertile
men (hSP1, hSP2), at the endogenous mIC1 and the targeted hIC1 in knock-in sperm (KISP)
from adult mice, and at the targeted hIC1 in pools of H19+/hIC1 two-cell stage embryos (KI2-cell)
are shown. KISP: n=6 mice, KI2-cell pools: n=3. Two-tailed Student's T-test with equal variance; *
(P<0.05). Bars represent the mean ± SEM; error bar of the KISP(mIC1) is too small to be seen on
the graph. (B) Methylation at hIC1 in KISP and hSP1 analyzed by bisulfite treatment followed by
sequencing; assays e-h are used (Figure 2.2C). Cytosines in CG dinucleotides that are
conserved between mouse and human and located within CTS are depicted as black lines above
the clones and marked as CTS 1,2,3,4, and 6 (Bell and Felsenfeld, 2000). Cytosines measured
by pyrosequencing are marked with an asterisk. (C) ChIP-qRT-PCR for H3K4me2 and H3K9me3
at the mIC1 and hIC1 in knock-in round spermatids; assays b and j were used (Figure 2.2C). Two
independent pools of round spermatids were generated as detailed in Chapter 5.6, and the
results from each pool are shown separately. Y-axis denotes the ChIP signal of each histone
mark normalized to that of total H3 (e.g. percent input H3K4me2/percent input total H3).
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Figure 2.10 Changes in levels of imprinted gene network (IGN) genes in H19+/hIC1 embryos
and placentas. For the y-axis, the mean value of +/+ is arbitrarily set as 1. (A,B) +/+: n=8,
+/hIC1: n=6 (from two litters). White bars: +/+, black bars: +/hIC1. P-value was calculated using
two-tailed Student's T-test with equal variance; * (P < 0.05); *** (P < 0.001). Bars represent the
mean ± SEM.
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Figure 2.11 Analyses of H19+/hIC1 placentas. (A) Representative cross-sections of E15.5 +/+
and +/hIC1 placentas stained with haematoxylin and eosin. Black lines outline the decidua (DC),
junctional zone (JZ), and labyrinthine zone (Lab). Scale bar represents 1000μm. (B) Stereological
analysis of the junctional zone (JZ) area to labyrinth zone (Lab) area ratio in E15.5 +/+ and
+/hIC1 placentas. (B) +/+: n=5, +/hIC1: n=4 (from one litter). Two-tailed Student's T-test with
equal variance; ** (P<0.01). Bars represent the mean ± SEM.
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Figure 2.12 Analyses of miR-675 and Igf1r in H19+/hIC1 embryos and placentas. (A) Total
expression of miR-675-3p and miR-675-5p in E15.5 livers and placentas, normalized to the level
of snoRNA202. (B) Total expression of Igf1r in E15.5 livers and placentas. (A,B) +/+: n=8, +/KI:
n=6 (from two litters). White bars: +/+, black bars: +/hIC1. (A,B) P-value was calculated using
two-tailed Student's T-test with equal variance; * (P < 0.05); **** (P < 0.0001). Bars represent the
mean ± SEM.
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Figure 2.13 Strategies to address the specific role of miR-675 and H19 in growth regulation.
(A) Top, H19/Igf2 regulation in the wild-type (H19+/+). Bottom, H19/Igf2 regulation upon paternal
transmission of the H19hIC1 allele (H19+/hIC1). (B) A schematic of a cross between H19+/miR-675mut
female and H19hIC1/+ male. (C) A schematic of a cross between H19+/ΔH19 female and H19hIC1/+
male. (B,C) Mutant or deletion alleles are indicated with striped boxes. The parent-of-origin of the
allele is indicated with a female(♀) or male (♂) symbol.
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Figure 2.14 CRISPR/Cas9 gRNA designs for deleting the H19 sequence. (A) Shown is the
endogenous mouse H19 (~2.5kb) sequence that is composed of five exons (E). Two pairs of
gRNA were designed: pair A (5A gRNA-3A gRNA) and pair B (5B gRNA-3B gRNA). Either pair A
or pair B was injected into zygote stage embryos. A set of primer (H19-214 and H19+2722) that
was used to genotype the deletion allele is indicated in pink. (B) A representative genotyping gel
of chimeras. Injection of either pair A or pair B generated chimeras with correct deletions. When
the H19 sequence is successfully deleted, the H19-214 and H19+2722 primer set amplifies ~200250bp fragments (size may vary depending on the indels generated). The amplified fragments
were gel-isolated and sequenced to confirm the deletions. Left most lane: 1kb+ ladder
(Invitrogen); lanes indicated with yellow asterisks: deletion alleles, otherwise: wild-type alleles.
The non-specific PCR band is indicated.
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Figure 2.15 day 0 neonatal weight analyses of the H19ΔH19 allele. (A) Paternal transmission of
the H19ΔH19 allele. +/+: n=6, +/△H19: n=8 (from two litters). (B) Maternal transmission of the
H19ΔH19 allele. +/+: n=10, △H19/+: n=10 (from three litters). (A,B) At least two different chimeric
founders (i.e. founder with different length of deletion) were used to generate litters. Each dot or
square on the graph represents individual pup. P-value was calculated using two-tailed Student's
T-test with equal variance; *** (P < 0.001), otherwise, not significant.
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Female germ cells

Somatic cells (hIC1/+)

Figure 2.16 Model for maternal transmission of the H19hIC1 allele. During the female germ cell
development, both hIC1 and mIC1 are properly hypomethylated. Once an egg carrying hIC1 is
fertilized with a sperm carrying mIC1 and develops into hIC1/+ somatic cells, the CTCFdependent insulator is properly formed on the maternal hIC1. This leads to the correct imprinted
expression of the H19/Igf2 locus. The parent-of-origin of the allele is indicated with a female(♀) or
male (♂) symbol.
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Male germ cells

Zygotes (+/hIC1)

Somatic cells (+/hIC1)

Figure 2.17 Model for paternal transmission of the H19hIC1 allele. During male germ cell
development, unlike mIC1, hIC1 is unusually enriched with H3K4me2, which is inhibitory to the de
novo DNA methyltransferase machinery. This leaves some regions of hIC1 (that are enriched
with H3K4me2) hypomethylated. Once a sperm carrying hIC1 fertilizes an egg carrying mIC1 and
develops into a zygote, CTCF binds to the unmethylated CTCF-binding sites at the hIC1. As the
zygote undergoes cell division and develops into +/hIC1 somatic cells, the partially established
methylation marks at hIC1 are not maintained, leading to a fully hypomethylated state of hIC1.
Ultimately, biallelic insulation at the locus is established, resulting in loss of imprinting. The
parent-of-origin of the allele is indicated with a female(♀) or male (♂) symbol.
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CHAPTER 3.
PATIENT-DERIVED HUMAN CELL BASED MODEL
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3.1 Background and study rationale
Patient samples expand our knowledge in imprinting. Investigating various
human mutations associated with imprinting disorders can provide additional insights
into how imprinting is regulated in human, which can be translated into therapeutic
strategies. Importantly, understanding mechanisms underlying mutations such as
pUPD11, that are harder to engineer in other model systems, can tremendously benefit
from analyzing the patient samples. However, these resources have limitations. First,
mosaicism is prevalent among BWS population: pUPD11 patients are mosaic for the
genetic mutations (Kalish et al., 2014), and individuals with IC1 microdeletions or OCT4binding mutations carry mosaic epimutations (Beygo et al., 2013; Demars et al., 2010;
Habib et al., 2014; Poole et al., 2012; Prawitt et al., 2005; Sparago et al., 2004). The
mosaic background of an individual can obscure the extent to which the specific
genetic/epigenetic mutation is sufficient to drive the phenotype of the patient. Second,
easily accessible yet disease non-relevant tissues, such as fibroblasts and blood, are not
the ideal surrogates to investigate the disease etiology. Thus, developing patient-derived
models that are devoid of mosaicism in the context of the disease-relevant cell types is
necessary.
iPSC technology allows derivation of clonal cell lines, where each cell line has a
uniform genetic and epigenetic background. Subsequently, these cell lines can be
differentiated into cell type of interest (Unternaehrer and Daley, 2011). These merits of
iPSC technology have led various common and rare disorders to be modeled in vitro,
including imprinting disorders such as Angelman syndrome and Prader-Willi syndrome
(Chamberlain et al., 2010; Cruvinel et al., 2014; Stelzer et al., 2014).
Previous reports have suggested a link between the imprinted genes and
pluripotency of stem cells, although no concrete consensus has been reached (Chang et
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al., 2014; Stadtfeld et al., 2010, 2012). The correct imprinted status of the DLK1-DIO3
locus (Figure 3.1) has received a wide attention as a molecular marker for assessing the
quality of stem cells (Benetatos et al., 2014). Hypermethylation and/or aberrant silencing
of the maternally expressed long non-coding RNAs and microRNAs at the DLK1-DIO3
locus have been linked to poor developmental potential of mouse iPSCs (Stadtfeld et al.,
2010; Stadtfeld et al., 2012), suboptimal pluripotency in mouse ESCs (Liu et al., 2010),
and inefficient neural lineage differentiation potential of human ESCs (Mo et al., 2015).
In contrast, Christodoulou et al. showed that mouse iPSCs with hypermethylated
Dlk1-Dio3 locus had similar differentiation capacity into definitive endoderm compared to
mouse ESCs with normal Dlk1-Dio3 methylation (Christodoulou et al., 2011). Chang et
al. noted that hypomethylation of the Zrsr1 imprinted gene, but not hypermethylation of
the Dlk1-Dio3 locus, is correlated with poor quality of mouse iPSCs (Chang et al., 2014).
Thus, the extent to which the DLK1-DIO3 locus hypermethylation affects iPSC quality
requires further investigation.
Other ICRs have infrequently exhibited stochastic aberrant DNA methylation in
both mouse and human pluripotent stem cells (Nazor et al., 2012; Nishino et al., 2011;
Sun et al., 2012; Takikawa et al., 2013). Overall, these studies emphasize the need for
careful examination of the stability of imprinted genes in the pluripotent stem cells. Such
inspection is especially crucial for the cell lines that will be used for therapeutic or
disease-modeling of imprinting disorders.
Here, we present derivation of the iPSCs from pUPD11 BWS patient fibroblasts
(Figure 3.2). We show that genetically-matched pUPD11 and non-pUPD11 iPSCs can
be derived from mosaic samples. We primarily analyzed DNA methylation at various
imprinted regions in our cell lines, and show that while other regions exhibit proper
methylation profile, the DLK1-DIO3 locus is aberrantly methylated. Although the
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significance underlying this molecular phenomenon remains to be determined, the
derived cell lines are useful resources that can be further differentiated into clinicallyrelevant endodermal and mesodermal lineages to examine molecular mechanisms
leading to BWS.
3.2 Derivation of iPSCs from mosaic pUPD11 fibroblasts
Skin samples from four male patients were collected during surgical procedures
and used to generate fibroblast cell lines. pUPD11 breakpoints as well as extent of
mosaicism of pUPD11 for all patients were determined using genome-wide singlenucleotide polymorphism (SNP) microarray analysis (Figure 3.3 and data not shown). To
demonstrate that two populations of cells, designated isogenic pUPD11 and nonpUPD11 iPSCs, can be derived from mosaic fibroblast cell lines, we reprogrammed
fibroblasts from these patients using either polycistronic STEMCCA lentivirus (Sommer
et al., 2009) or episomal plasmids (Okita et al., 2011). As a sex- and cell-type- matched
control, we reprogrammed one male fibroblast cell line (IMR91) using episomal plasmids
(Figure 3.3). Most of the iPSC-like colonies were isolated, and the clones that thrived for
at least three passages were counted and noted in Figure 3.3. All fibroblast cell lines and
representative iPSC lines had a normal karyotype (data not shown). The iPSCs
expressed similar levels of pluripotency markers and all three embryonic germ layer
markers upon differentiation into embryoid bodies (EBs) as measured by qRT-PCR and
immunofluorescence (Figure 3.4, 3.5A, and 3.5B), regardless of the reprogramming
strategy or the extent of pUPD11 in the parental fibroblasts. To determine which iPSCs
had pUPD11 versus biparental chromosome 11, we used microsatellite fragment
analyses or restriction fragment length polymorphisms (Table 5.4). Notably, the percent
of pUPD11 iPSC clones derived relative to the total number of iPSC clones was
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reflective of the percent pUPD11 in the initial fibroblasts (Figure 3.3). We did not obtain
any pUPD11 iPSCs from patient 2 fibroblasts (Figure 3.3), likely due to the low level of
pUPD11 in the initial fibroblasts. These results demonstrate that pUPD11 and nonpUPD11 iPSCs can be derived from a mosaic patient fibroblast sample.
3.3 Analyses of the pUPD11-relevant ICRs and imprinted genes
DNA methylation status at IC1 and IC2 is the most widely used molecular marker
to diagnose BWS (Mussa et al., 2016). Thus, it is essential that iPSCs derived to model
BWS display normal and intact methylation profile at both ICRs. To determine that
pUPD11 and non-pUPD11 iPSCs reflect the DNA methylation status of the parental
fibroblasts, IC1 and IC2 methylation levels were measured. For IC1 methylation
analyses, we performed pyrosequencing for patient 1 and 2 cell lines. Due to the
presence of SNPs in the pyrosequencing primer binding site for patient 3 and 4 cell lines,
combined bisulfite restriction analysis (COBRA) was used. IC2 methylation for all patient
lines was analyzed using COBRA. Because pUPD11 iPSCs have two copies of the
paternal contribution of the IC1 (Figure 1.8), they exhibited ~100% methylation as
expected, and non-pUPD11 iPSCs displayed the expected ~50% methylation (Figure
3.6A). To validate the COBRA results, IC1 methylation in the patient 3 and 4 fibroblast
cell lines and select non-pUPD11 and pUPD11 iPSCs was determined using bisulfite
treatment followed by direct sequencing. The sequencing results replicated the COBRA
results (Figure 3.6B). Because the paternally inherited IC2 is normally unmethylated, as
expected, all pUPD11 iPSCs analyzed showed no detectable methylation at IC2 (Figure
3.7), whereas non-pUPD11 iPSCs showed normal methylation. Therefore, IC1 and IC2
methylation status is appropriate for the parent-of-origin and is maintained after the
derivation and culture of iPSCs.
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To investigate whether DNA methylation is stably maintained across multiple
passages, select patient 1 and 2 iPSCs were cultured over prolonged periods. All iPSCs
maintained stable IC1 methylation pattern in later passages (Figure 3.8), demonstrating
that the reprogramming and/or culture conditions for iPSCs does not perturb IC1
methylation in our study.
Next, we evaluated expression of imprinted genes in the pUPD11 region.
Because H19 and Igf2 are lowly expressed in the mouse blastocysts (Lee et al., 1990;
Poirier et al., 1991), we did not expect to observe high levels of expression of these
genes in iPSCs. Consistently, expression of both genes was low in iPSCs. Therefore, we
differentiated iPSCs into EBs to examine H19 and IGF2 RNA levels. pUPD11 EBs
displayed no expression of H19, whereas non-pUPD11 EBs expressed H19.
Furthermore, pUPD11 EBs expressed higher levels of IGF2 compared to the nonpUPD11 EBs (Figure 3.9). These results demonstrate that H19 and IGF2 mRNA in EBs
appropriately reflect their non-pUPD11 versus pUPD11 statuses of their counterpart
iPSCs.
3.4 Analyses of DNA methylation at other ICRs
We also analyzed imprinted loci outside of the pUPD11 region. First, we
analyzed DNA methylation at the SNRPN ICR, implicated in Prader-Willi syndrome
(Cassidy et al., 2012) using pyrosequencing. All iPSCs showed normal methylation
levels at the SNRPN ICR similar to the level detected in the parental fibroblasts (Figure
3.10). Hence, reprogramming strategies employed in the current study lead to stable
methylation status at the SNRPN ICR.
Next, we examined the DLK1-DIO3 locus using pyrosequencing. Here, we
analyzed two DMRs—the intergenic differentially methylated region (IG-DMR), which
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serves as the locus ICR, and the MEG3-DMR, a paternally methylated sequence that
reflects the MEG3 imprinted expression (Figure 3.1) (Benetatos et al., 2014). Consistent
with previous reports, many iPSC clones were abnormally hypermethylated at the DLK1DIO3 locus, in contrast to their initial parental fibroblasts, which were normally
methylated (Figure 3.11A). To address whether prolonged culture had additional effects
on DNA methylation stability at the locus, select patient 1 and 2 iPSCs were cultured
over prolonged periods. Some clones (i.e. patient 1 clone 43, patient 2 clones 68 and
76) became hypermethylated over extended culture at one or both DMRs (Figure 3.11B),
suggesting that aberrant methylation can manifest during prolonged culture. We also
observed that different aliquots of the same iPSC line thawed independently exhibited
variable DNA methylation patterns (data not shown). Nevertheless, some clones (i.e.
patient 1 clone 9 and patient 2 clone 61) maintained normal methylation for 7-10
passages (Figure 3.11B). Overall, these results suggest that the DLK1-DIO3 locus is
especially sensitive to DNA methylation perturbation during iPSC reprogramming and/or
culture.
3.5 The effect of vitamin C in ICR methylation
Several groups have advocated the use of vitamin C (VC) supplementation
during iPSC reprogramming for enhancing the efficiency of reprogramming and/or
generating high-quality mouse and human iPSCs (Chen et al., 2013; Esteban et al.,
2010; Stadtfeld et al., 2012; Xu et al., 2015). To this end, we reprogrammed the IMR91
fibroblast cell line with (+VC) or without VC (-VC) in parallel experiments; 18+VC and 17VC IMR91 iPSC clones were isolated (Figure 3.3). The efficiency of expanding viable
clones was the same regardless of VC exposure. IC1, IC2, and SNRPN ICR maintained
normal methylation levels in the IMR91 iPSCs regardless of VC treatment (Figure 3.12A
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and B). Interestingly, we noticed that VC leads to an initial, average, lower methylation
level at both IG-DMR and MEG3-DMR in iPSCs (Figure 3.13A). All clones examined,
however, became hypermethylated at IG-DMR and MEG3-DMR in later passages,
irrespective of the VC treatment (Figure 3.13B).
3.4 Discussion
In this study, we report the establishment of iPSC models of BWS. We derived
both pUPD11 and non-pUPD11 iPSCs from three BWS patient fibroblast cell lines that
have distinct pUPD11 regions and differing levels of mosaicism for pUPD11 in the
parental fibroblasts. In each reprogramming experiment, the non-pUPD11 iPSCs serve
as internal controls for pUPD11 iPSCs, as the cell lines are isogenic except for the
pUPD11 regions. The use of matched iPSCs to study human diseases diminishes
potential background effects caused by genetic variations between individuals. To our
knowledge, these lines are the first iPSC models of BWS, thus a valuable tool to study
the mechanisms of IC1 and IC2 imprinting in BWS.
Importantly, we showed that the proportion of the pUPD11 iPSC lines relative to
the total iPSC lines reflects the percent of pUPD11 cells in the patient fibroblasts. These
results suggest that during reprogramming, the pUPD11 cells do not have growth
advantages, even though the growth-promoting gene, IGF2, is overrepresented and the
growth-suppressing genes, CDKN1C and H19 are repressed in these cells. Lack of a
growth advantage is likely due to relatively low expression of the genes during the
reprogramming process and propagation of iPSCs, as we showed that H19 and IGF2
expression is low in the iPSCs yet increased upon differentiation into EBs. Similarly,
CDKN1C is significantly upregulated upon human ESCs differentiation into EBs
(Bhattacharya et al., 2005).
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We examined DNA methylation at five DMRs in the iPSCs: IC1, IC2, SNRPN ICR,
IG-DMR, and MEG3-DMR, and showed that methylation was properly maintained at IC1,
IC2 and SNRPN ICR. However, we observed a prevalence of hypermethylation at the
DLK1-DIO3 locus in the iPSCs, as reported by others (Benetatos et al., 2014). To what
extent the DLK1-DIO3 locus hypermethylation affects human iPSC quality remains
unclear. Mo et al. inferred that hypermethylation at the DLK1-DIO3 locus results in
inefficient ectodermal differentiation (Mo et al., 2015). However, EB samples
differentiated from the non-pUPD11 and pUPD11 iPSCs with hypermethylated DLK1DIO3 locus expressed similar levels of the ectodermal markers compared to the EB
sample (patient 1, pUPD11 clone 9) differentiated from the iPSCs with a normal DLK1DIO3 methylation. The discrepancy between the two studies may be attributed to the
different cell sources (human ESCs vs iPSCs) and culture techniques. Nevertheless,
appropriate expression of germ lineage markers in all EBs analyzed suggests that our
iPSCs have normal differentiation potential into all three germ lineages independent of
the methylation status at the DLK1-DIOS locus.
We showed that the VC supplementation during iPSC reprogramming was
associated with a significantly lower methylation level at the DLK1-DIO3 locus in the
early passage iPSCs compared to the iPSCs derived without VC supplementation,
consistent with the results obtained by Stadtfeld et al. where addition of VC during
reprogramming suppressed hypermethylation at the Dlk1-Dio3 locus in mouse iPSCs
(Stadtfeld et al., 2012). However, in our study, the iPSCs in the +VC group became
hypermethylated over extended culture. Whether the mouse iPSCs with normal Dlk1Dio3 methylation in the study by Stadtfeld et al. maintained their methylation over
extended culture is unclear. However, it is possible that VC affects the mouse and
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human DLK1-DIO3 locus differently, through its influence on multiple epigenetic
regulators such as histone demethylases and DNA demethylases (Blaschke et al., 2013;
Chen et al., 2013; Eid and Abdel-Rehim, 2016; Gao et al., 2015; Shi et al., 2010; Wang
et al., 2011).
3.5 Contributions
The work described in this chapter is a collaborative effort. Dr. Jennifer Kalish
collected the patient samples, performed SNP array, and provided general advice for the
project. Dr. Montserrat Anguera provided pivotal guidance in deriving and characterizing
iPSCs. Dr. Joanne Thorvaldsen performed iPSC reprogramming. Dr. Dong Hun Woo,
currently at the NEXEL Co., Ltd, Seoul, Korea, provided STEMCCA lentivirus. Suhee
Chang, from the laboratory of Dr. Marisa Bartolomei, Carolyn Lye, currently at the Yale
medical school, and Alice Yu, from the laboratory of Dr. Jennifer Kalish, assisted in
various aspects of iPSC characterization. Dr. Joanne Thorvaldsen and Suhee Chang
have significantly contributed in expanding and analyzing iPSCs.

78

Figure 3.1 DLK1-DIO3 imprinted locus in human 14q32. On the maternal allele (♀), lncRNA
MEG3 as well as a large cluster of miRNAs and snoRNA are active. On the paternal allele (♂),
protein-coding genes including DLK1, RTL1, and DIO3 are expressed. The IG-DMR serves as
the ICR for the locus, and DNA methylation at the MEG3-DMR is established in the somatic cells.
Both IG-DMR and MEG3-DMR are methylated on the paternal allele. Centromeric (C) and
telomeric (T) ends are indicated. Not drawn to scale.
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Figure 3.2 A schematic of pUPD11 fibroblasts reprogramming. Mosaic pUPD11 fibroblasts
consist of both non-pUPD11 (represented in grey) and pUPD11 (represented in pink) cells. When
these fibroblasts are reprogrammed using the four Yamanaka factors (OCT4, KLF4, SOX2, CMYC) (Takahashi and Yamanaka, 2006), cell lines that are purely non-pUPD11 or pUPD11 are
derived. These iPSCs can be differentiated into lineage of interest, such as endoderm or
mesoderm.
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Figure 3.3 Summary of iPSC reprogramming in this study. A schematic illustrating
chromosome 11 with relative locations of IC1 and IC2 as well as regions of pUPD11 (colored
retangles) of each pUPD11 fibroblast cell line (Patient 1, 2, 3, 4). pUPD11 break points are
indicated next to regions of pUPD11 (Human Genome Build 37, hg19, 2009). Percent pUPD11 in
the parental fibroblasts, methods of reprogramming, use of vitamin C during reprogramming, and
numbers of total, non-pUPD11, and pUPD11 iPSC clones derived, of four pUPD11 fibroblast cell
lines and one control fibroblast cell line (IMR91) are summarized. NA: not applicable.
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Figure 3.4 Phase-contrast and immunofluorescence images of human iPSCs. Expression of
pluripotency markers (SSEA3, SSEA4, TRA1-60, TRA1-81 and OCT4) in select iPSC clones.
SSEA1 was used as a negative control cell surface marker for iPSCs. Scale bars, 100𝜇m.
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Figure 3.5 Expression of pluripotency markers in iPSCs and expression of germ lineage
markers, H19, and IGF2 in EBs. (A) Expression of pluripotency markers in the iPSCs was
measured by qRT-PCR. Expression in the iPSCs were normalized to expression in the respective
parental fibroblasts (set to 1). Fib: fibroblasts. (B) Expression of germ lineage markers in the EBs
measured by qRT-PCR. Endoderm markers: AFP and GATA4; mesoderm markers: HAND1 and
RUNX2; ectoderm markers: NACM1 and FGF5. Expression in the EBs were normalized to
expression in the counterpart iPSCs (set to 1). (A,B) Labels on X-axis denote patient
number/IMR91 followed by clone number (i.e. 1_5: patient 1 clone 5, IMR91_37: IMR91 clone 37).
Y-axis is in log base 10 scale. pUPD11 clones are highlighted in grey boxes; otherwise, nonpUPD11.
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Figure 3.6 Methylation at IC1 in iPSCs and fibroblasts. (A) Methylation at IC1 was measured
by pyrosequencing (in patient 1 and 2 cell lines) and COBRA (in patient 3 and 4 cell lines). Each
graph includes results from the parental fibroblast cell line (dotted bar) and hiPSCs derived from
the respective fibroblast cell line (solid bars). Labels on X-axis denote clone number followed by
passage number (i.e. 1p9: clone number 1 at passage 9). pUPD11 clones are highlighted in grey
boxes; otherwise, non-pUPD11. (B) IC1 methylation of patient 3 and 4 fibroblasts and iPSCs
measured by bisulfite treatment followed by direct sequencing.
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Figure 3.7 Methylation at IC2 in iPSCs and fibroblasts. All samples were analyzed by COBRA.
Bars for the pUPD11 iPSCs are too small to be seen on the graph. Each graph includes results
from the parental fibroblast cell line (dotted bar) and hiPSCs derived from the respective fibroblast
cell line (solid bars). Labels on X-axis denote clone number followed by passage number (i.e.
1p9: clone number 1 at passage 9). pUPD11 clones are highlighted in grey boxes; otherwise,
non-pUPD11.

85

Figure 3.8 Methylation at IC1 in select patient 1 and 2 iPSCs during extended culture. Bars
are grouped by clones. Each graph includes results from the parental fibroblast cell line (dotted
bar) and hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis
denote clone number followed by passage number (i.e. 1p9: clone number 1 at passage 9).
pUPD11 clones are highlighted in grey boxes; otherwise, non-pUPD11.
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Figure 3.9 Expression of H19 and IGF2 in iPSCs and EBs measured by qRT-PCR. H19
expression (left graph) in the iPSCs are indicated in light red bars and EBs in dark red bars. IGF2
expression (right graph) in the iPSCs are indicated in light blue bars and EBs in dark blue bars.
Note scale breaks on the y-axes for both graphs. Bars for the pUPD11 clones as well as some
iPSCs on the left graph are too small to be seen. Some bars for the iPSCs on the right graph are
too small to be seen. Labels on X-axis denote patient number/IMR91 followed by clone number
(i.e. 1_5: patient 1 clone 5, IMR91_37: IMR91 clone 37). pUPD11 clones are highlighted in grey
boxes; otherwise, non-pUPD11.
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Figure 3.10 Methylation at SNRPN ICR in iPSCs and fibroblasts. All samples were analyzed
by pyrosequencing. Each graph includes results from the parental fibroblast cell line (dotted bar)
and hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis denote
clone number followed by passage number (i.e. 1p9: clone number 1 at passage 9). pUPD11
clones are highlighted in grey boxes; otherwise, non-pUPD11.
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Figure 3.11 Methylation at IG-DMR and MEG3-DMR in iPSCs and fibroblasts. Methylation at
IG-DMR and MEG3-DMR were analyzed by pyrosequencing. (A) Methylatoin at IG-DMR and
MEG3-DMR in all patient cell ilnes (B) Methylation at IG-DMR and MEG3-DMR in select patient 1
and 2 iPSCs during extended culture. Bars are grouped by clones. (A,B) pUPD11 clones are
highlighted in grey boxes; otherwise, non-pUPD11. Methylation at IG-DMR is indicated in dark
blue bars and MEG3-DMR in light blue bars. Each graph includes results from the parental
fibroblast cell line (dotted bar) and hiPSCs derived from the respective fibroblast cell line (solid
bars). Labels on X-axis denote clone number followed by passage number (i.e. 1p9: clone
number 1 at passage 9). pUPD11 clones are highlighted in grey boxes; otherwise, non-pUPD11.
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Figure 3.12 IC1, IC2, and SNRPN ICR methylation in IMR91 iPSCs derived from +VC or -VC
reprogramming. (A) Methylation at IC1 was measured by pyrosequencing. ns, not significant;
two-tailed student’s t test with unequal variance. (B) Methylation at IC2 and SNRPN ICR was
measured by COBRA and pyrosequencing, respectively. (A,B) iPSCs derived from +VC
reprogramming are highlighted in yellow boxes; otherwise, derived from -VC reprogramming.
Each graph includes results from the parental fibroblast cell line (dotted bar) and hiPSCs derived
from the respective fibroblast cell line (solid bars). Labels on X-axis denote clone number
followed by passage number (i.e. 1p9: clone number 1 at passage 9).
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Figure 3.13 DLK1-DIO3 locus methylation in IMR91 iPSCs derived from +VC or -VC
reprogramming. (A) Methylation at IG-DMR and MEG3-DMR was measured by pyrosequencing.
**, p<0.01; two-tailed student’s t test with unequal variance. (B) Methylation at IG-DMR and
MEG3-DMR in select iPSCs during extended culture. Bars are grouped by clones. (A,B) iPSCs
derived from +VC reprogramming are highlighted in yellow boxes; otherwise, derived from -VC
reprogramming. Methylation at IG-DMR is indicated in dark blue bars and MEG3-DMR in light
blue bars. Each graph includes results from the parental fibroblast cell line (dotted bar) and
hiPSCs derived from the respective fibroblast cell line (solid bars). Labels on X-axis denote clone
number followed by passage number (i.e. 1p9: clone number 1 at passage 9).
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CHAPTER 4.
FUTURE DIRECTIONS
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4.1 Humanized mouse model
Disease modeling of BWS
IC1 alterations associated with BWS manifest clinical phenotypes when the
mutant allele is maternal in origin (Figure 1.7). It is thought that the disrupted insulator
function of IC1 on the maternal allele leads to biallelic expression of IGF2 and reduced
H19 expression, contributing to the overgrowth phenotype. Interestingly, however, these
alterations exhibit mosaic gain of methylation at IC1, suggesting that not all cells are
aberrantly DNA methylated (Sparago et al., 2004; Prawitt et al., 2005; Beygo et al.,
2013; Poole et al., 2012; Demars et al., 2010; Abi Habib et al., 2014). In addition, the
penetrance of BWS clinical features ranges from no apparent phenotypes to severe
growth defects (Beygo et al., 2013; Abi Habib et al., 2014). Thus, it is challenging to
address if the genetic lesions are sufficient to cause abnormal IC1 hypermethylation,
deregulation of H19/IGF2 imprinting, and/or development of BWS. The correlation
between methylation changes and genetic lesions suggest heritability of pathological
epigenotype, making the molecular investigation of these mutations particularly
important.
In this study, we showed that maternal transmission of hIC1 can functionally
replace mIC1, by properly regulating imprinted expression and hIC1 methylation. Thus,
our finding poses the exciting possibility of modeling IC1 mutations associated with BWS
(Figure 1.7) in mouse via maternal transmission. This endeavor has been initiated in
collaboration with the laboratory of Dr. Andrea Riccio. Mouse models with 1.8kb and
2.2kb IC1 microdeletions (Figure 1.7) were generated in a similar manner to the H19hIC1
allele, and both alleles are currently being analyzed. Preliminary data suggest that
maternal transmission of both alleles leads to biallelic Igf2 expression, gain of
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methylation at IC1, and overgrowth phenotype (personal communication with Dr. Andrea
Riccio). It will be interesting to compare the phenotypes of mice inheriting the two
microdeletion alleles. Of note, Beygo et al. reported that individuals with 2.2kb deletion
exhibit less severe clinical phenotypes compared to those with 1.8kb deletion (Beygo et
al., 2013).
Disease modeling of SRS
Despite IC1 hypomethylation being the most common epimutation found among
SRS individuals (Figure 1.6) (Yamazawa et al., 2008), the molecular mechanism
underlying the phenotype remains elusive. Obstacles in addressing this question include
mosaicism of the epimutation in patients as well as lack of a suitable genetic model
system. We suggest that the paternal transmission of hIC1 in a mouse can be used to
study molecular mechanisms underlying SRS associated with IC1 hypomethylation. To
this end, pursuing the rescue experiments with the H19△H19 and the H19miR-675mut alleles
(Chapters 2.8.1 and 2.8.2) will elucidate the extent to which H19 lncRNA and miR-675
contribute to the SRS-like phenotype. In addition, identifying tissue-specific (i.e.
embryonic endodermal and mesodermal tissues and extraembryonic tissues) pathways
altered by IC1 hypomethylation may shed light on whether the phenotypes underlying
SRS are due to an altered physiology of one particular tissue or due to a combinatorial
change in multiple tissues.
Investigating the species-specific regulation of the H19/Igf2 locus
Evidence of incomplete histone reprogramming at hIC1 suggests that the
mechanism regulating histone reprogramming at IC1 in the germline has diverged
between mouse and human. In this regard, it would be interesting to determine if an IC1
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ortholog of a species more closely related to mouse could recapitulate the wild-type
epigenetic pattern upon paternal transmission. This approach will provide insights into
the extent to which mechanisms regulating the ICR reprogramming in the germline are
conserved across mammalian evolution. Of note, recent studies have identified different
features of germline epigenetic reprogramming between mouse and human.
Interestingly, DNA methylation erasure at ICRs starts earlier in development in human
(before PGCs colonize the genital ridges) compared to mouse (upon PGCs colonization
of the genital ridges) (Gkountela et al., 2015; Guo et al., 2015; Hackett et al., 2013; Tang
et al., 2015). The precise timing of DNA methylation establishment in the human germ
cells remains to be determined. Nonetheless, differences in the length of gestation or the
timing of developmental cues might account for the incomplete reprogramming of hIC1
in mouse.
It is also possible that in the normal human context, the maternal hIC1 has a
novel regulatory function (that is not present in mouse) of silencing the IGF2 expression
and enhancing H19 expression. This human-specific function of the maternal hIC1 may
be incompatible with the mouse system, acting dominantly on the mouse paternal allele.
Such a neomorphic allele could recruit unknown transcription factors or form a specific
three-dimensional chromatin conformation and/or an epigenetic landscape by recruiting
chromatin modifying enzymes, leading to a preferential expression of H19, while
silencing Igf2 expression. This hypothesis could be tested by generating an allele where
hIC1 is inserted next to the endogenous mIC1. Imprinted expression of H19 and Igf2 and
DNA methylation and histone modification at the locus can be measured. If hIC1 has a
dominant effect in abrogating the normal function of the mIC1 on the paternal allele, this
could suggest a neomorphic function of hIC1 (or potentially a novel regulatory role of
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endogenous hIC1), although the possibility of hIC1 acting as a dominant CTCFdependent insulator compared to mIC1 cannot be excluded. If having an intact mIC1 at
the endogenous locus preserves the normal imprinting function and male germline
reprogramming of the hIC1 sequence, this will argue against the idea of hIC1 acquiring a
neomorphic function. This result would rather suggest that the insertion of hIC1 can be
influenced by the surrounding sequence or epigenetic landscape at the locus.
Male germ cell analyses
Given the well-described antagonistic relationship between the activating histone
modification marks and DNA methylation (Chapter 1.1.2), we speculate that the
abnormal enrichment of H3K4me2 at the hIC1 is inhibitory to the complete establishment
of DNA methylation. However, it is equally possible that the hypomethylated state of
DNA has attracted H3K4me2 at hIC1 by an unknown mechanism. More detailed time
course analyses of DNA methylation and H3K4me2 enrichment in the PGCs and early
stage male germ cells, such as spermatogonia, will provide insights into such an
hypothesis.
Alternatively, there might exist an inherent difference between mIC1 and hIC1 in
acquisition of methylation. A non-coding transcript is detected at mIC1 during
methylation acquisition in the male germ cells (Henckel et al., 2012), suggesting a
potential role of transcription in methylation establishment at mIC1. Whether the same
holds true at the endogenous hIC1 remains to be determined. Nevertheless, it would be
worth investigating whether the expression of the non-coding transcript is disrupted in
the male germ cells upon replacement of the mIC1 with hIC1. This result will support the
growing agreement that transcription plays an important role in DNA methylation
establishment at the ICRs, at least in mouse.
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4.2 Patient-derived human cell based model
Lineage-specific differentiation of the iPSCs
The iPSCs derived exhibit stable and expected DNA methylation status at the
pUPD11-relevant ICRs—IC1 and IC2. We also verified that pUPD11 EBs express higher
levels of IGF2 compared to the non-pUPD11 EBs. To characterize pUPD11 in a
disease-relevant context, we plan to differentiate select iPSC lines into hepatocytes. This
work is ongoing in collaboration with the CHOP human ES/iPS cell core facility. The
stability of methylation at IC1 and IC2 and the expression of H19 and Igf2 during
different stages of differentiation will be carefully monitored. Ultimately, our goal is to
perform RNA-sequencing in the cell lines to identify molecular pathways affected by
pUPD11. Comparing gene expression profiles of different pUPD11 lines may shed light
on the contribution of non-imprinted genes within the UPD region in the BWS disease
etiology. Moreover, the non-pUPD11 iPSCs can be engineered to model other IC1
mutations (Figure 1.7). Establishment of these genetically-matched cell lines will
facilitate deconstructing the genotype-phenotype relationship in BWS.
DLK1-DIO3 hypermethylation
The significance of hypermethylation of the DLK1-DIO3 locus in iPSCs is unclear.
Different parental cell sources, culture conditions, and passaging techniques used in the
reprogramming experiments make it difficult to identify the source for this
hypermethylation (Nazor et al., 2012). Several groups have investigated the
mechanisms underlying the DLK1-DIO3 hypermethylation, and found the involvement of
post-translational histone modifying enzymes, DNA methyltransferases, long non-coding
RNAs, and maternal factors (Kaneko et al., 2014; McDonald et al., 2016; Stadtfeld et al.,
2010, 2012; Stelzer et al., 2014; Xu et al., 2015). Of note, individuals with pUPD14, in
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which maternally expressed non-coding RNAs are repressed and paternally expressed
protein-coding genes are upregulated, display postnatal growth and mental retardation
and skeletal defects (Rocha et al., 2008). These suggest that the regulation at this locus
is complex and its effect in human iPSC quality merits further investigation.
The effect of VC in DLK1-DIO3 hypermethylation
In the IMR91 fibroblasts reprogramming experiment with and without VC, failure
to maintain the DLK1-DIO3 methylation might be attributed to the insufficient dosage or
duration of VC treatment. It will be interesting to see whether further culturing the human
iPSCs with VC could revert the DLK1-DIO3 hypermethylation. Of note, culturing the
mouse iPSCs with VC for 15 passages did not revert the Dlk1-Dio3 hypermethylation
(Stadtfeld et al., 2012), suggesting that VC is mainly effective in the early stage of
mouse iPSC reprogramming at this locus. Nevertheless, dose-response and time-course
experiments of the VC supplementation during human iPSC reprogramming/culture will
elucidate the extent to which VC protects the human DLK1-DIO3 locus from becoming
hypermethylated.
4.3 Conclusions
Study of genomic imprinting is meaningful in understanding mammalian
development and human health. In addition, the unique but conserved regulation of
genomic imprinting can provide insights into mammalian evolution at both molecular and
physiological level. Proper regulation of genomic imprinting requires correct epigenetic
reprogramming in the germline as well as stable maintenance of the imprinted state in
the somatic cells. Therefore, comprehensive knowledge on mechanisms of genomic
imprinting requires studies in various cell types including embryonic, extraembryonic,
and germ cell lineages, at various developmental stages. Similarly, it is likely that
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mechanisms underlying alterations associated with human imprinting disorders are
highly context-and stage-dependent. Because it is not always feasible to perform
experiments in the desired cell types of the right developmental stage, especially with
human samples, developing and taking advantage of various model systems is crucial in
the study of genomic imprinting. The use of the humanized mouse model and the
patient-specific iPSCs to interrogate mechanisms of imprinting, described in this
dissertation, represents an example of such an endeavor. Continuous efforts in
developing diverse models, by recognizing the limitations while maximizing the benefits
of each model system, are instrumental to the field of imprinting.
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CHAPTER 5.
MATERIALS AND METHODS

100

5.1 Generation of H19hIC1 mouse
Targeting vector
To generate the phIC1-neo target vector, first the backbone KpnI site was
removed from the Δ3.8kb-5’ target vector (Thorvaldsen et al., 2002), leaving a unique
KpnI site between the 5’ homology arm and the NeoR cassette. Into this KpnI site, we
cloned the 4.8kb hIC1 sequence (from NsiI to EcoRI) isolated from human genome
library that was engineered to contain KpnI sites (at the NsiI and XhoI sites) without
destroying the endogenous sites (Stratagene) (Stadnick et al., 1999). The phIC1-neo
target vector was designed to replace both the endogenous mouse IC1 and 1.3 kb Grich repeat sequence with the hIC1 sequence, to make the distance between the
targeted hIC1 and the H19 promoter equivalent to what is observed at the orthologous
human locus. We have previously shown that the G-rich repeat sequence is dispensable
for normal H19/Igf2 imprinting in mouse (Thorvaldsen et al., 2002).
ESC targeting, mouse breeding, and genotyping
phCI1-neo target vector was linearized and electroporated into E14 ESCs (Kühn
et al., 1991) as described previously (Thorvaldsen et al., 2002). G418-resistant positive
clones were isolated and correct targeting was validated by Southern blot analyses
using the same external probes as described previously (Thorvaldsen et al., 2002) with
following changes. gDNA was digested with EcoRV-MluI and hybridized to the 5’probe A.
The internal probe C was isolated by PCR amplification of a WT B6 mouse gDNA using
primers 5’-ATTCCTCTCCAACCCTAGCTCAG-3’ and 5’GGATCTGCCAAGGTGCTATTGC-3’ and hybridized to gDNA digested with StuI (Figure
2.2A and B). Correctly targeted clones were injected into B6 blastocysts by the
Transgenic and Chimeric Mouse Facility at the University of Pennsylvania. Obtained
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chimeras were mated to B6 mice. Germline transmission of the targeted allele was
confirmed within the agouti progeny by isolating gDNA from ear punch samples and
performing Southern blot analysis as described above and PCR-based genotyping with
primers PGNeo0.2 and HSEQR1 (Tables 5.1 and 5.2). All studies adhered to
procedures approved by the Institutional Animal Care and Use Committee at the
University of Pennsylvania.
Germline transmission of the H19hIC1-neo was verified by PCR-based genotyping
as described above. To excise the neoR cassette (flanked by loxP sites), heterozygote
female mice with H19hIC1-neo allele were crossed to B6 male mice that express Cre
recombinase under the control of the adenovirus EIIa promoter (EIIA-Cre) (Jackson
laboratories). NeoR excision was verified using Southern blot analysis and PCR-based
genotyping with primers HIC1SEQF1 and TV23armSEQR1 (Figures 2.2A and B and
Tables 5.1 and 5.2). Mice lacking the NeoR cassette (H19hIC1) were maintained by
crossing the H19hIC1/+ female mice to wild-type B6 male mice and selecting for progeny
carrying the H19hIC1 allele as determined by PCR analysis. For all comparisons,
heterozygous knock-in offspring and embryos were compared with their wild-type
littermates. Both males and females were included. For all genotypes, the maternal
allele is listed first and the paternal allele second.
5.2 Generation of H19△H19 mouse
gRNA design
gRNA sequences were designed using the program (http://www.genomeengineering.org/crispr/?page) and are shown below. PAM sequences are underlined. 3A
and 3B target 3’end, and 5A and 5B target 5’end of the H19 gene.
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3A
5A

Pair A
CTTCAATATAATGCGACTCA TGG
AACGTGCGCTGGAACGATAC AGG

3B
5B

Pair B
CAATATAATGCGACTCATGG GGG
ATCAGTACATGGCCCCGCCG GGG

gRNA generation and injection
All procedures were done per guidance of Dr. Catherine May in the laboratory of
Dr. Klaus Kaestner. The protocol provided by Dr. Catherine May was modified from
Yang et al. (Yang et al., 2014). For sgRNA preparation, px335 plasmid (Addgene
#42335) was PCR amplified using the primer sets:
Forward: 5’-TTAATACGACTCACTATAGGNNNNNNNNNNNNNNNNNNNNgttttagagctagaaatagc3’
Reverse: 5’-AGCACCGACTCGGTGCCACT-3’

The underlined 20 nucleotides of the forward primer were substituted with each
gRNA sequence excluding the PAM sequence. Reverse primer is universal for all PCR
reactions. PCR reaction was setup using the Phusion high-fidelity DNA polymerase
(NEB, cat. No. M0530). To get enough materials for in vitro transcription, 2-3 PCR
reactions were setup per gRNA.
Component
5X Phusion HF Buffer
10mM dNTPs
10uM Primer Mix
DNA Polymerase
Template DNA (pX335), 10 ng
H2O
Total Volume
Cycle number
1
2-34
35
Hold at 4 °C

Denature
98 °C, 30s
98 °C, 30s

Amount (μl/reaction)
20
2
5
1
2
70
100
Anneal & Extend

Final Extend

72 °C, 20s
72 °C, 1 min

PCR products were ran on a 2% agarose gel. Once ~117bp products are verified,
PCR products are gel-purified using the Qiagen Gel Extraction kit according to the
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manufacturer’s instruction. One column was used to pool the same PCR product and
DNA was eluted in 15μl RNAse free water. In vitro transcription of gRNA was setup
using the gel-purified product as templates. T7 High Yield RNA Synthesis kit (NEB,
E2040S) was used according to the kit protocol. More than 2 tubes of reactions per
gRNA were setup to increase the yield.

Component

Amount (μl/reaction)

10X Reaction Buffer

1.5

ATP

1.5

GTP

1.5

UTP

1.5

CTP

1.5

Template DNA (500 ng)

X

T7 RNA polymerase Mix

1.5

Nuclease-free H2O

X

Total

20

Reactions were incubated at 37°C overnight. Transcribed gRNA was purified
using the MEGAclear kit (Life Technologies) according to the kit protocol. To prevent the
injection needles from being clogged during microinjection, the eluted gRNA was spun
twice at top speed at 4°C for 20min, with each spin followed by transfer of suspension to
a new tube. The eluted gRNA was concentrated according to the protocol so that the
final concentration is around 1-2μg/μl. RNA quality and quantity were checked using a
bioanalyzer. Injection mix was prepared as follow:

Component

Stock
Concentration

Stock Vol. (ul)

Final Concentration

sgRNA (Left)

500 ng/μl

3

50 ng/μl

sgRNA (Right)

500 ng/μl

3

50 ng/μl

Cas9 mRNA

1 μg/μl

3

100 ng/μl

Injection buffer*

21

Total

30
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*Injection buffer: 10 mM Tris / 0.1 mM EDTA, pH 7.5 prepared with sterile water.
The injection mix was spun at top speed at 4°C for 20min, and the suspension
was transferred to a new tube for injection. Either pair A or pair B was injected per
zygote stage embryo by the Transgenic and Chimeric Mouse Facility at the University of
Pennsylvania.
Mouse breeding and genotyping
Obtained chimeras and germ line transmission animals were PCR-genotyped for
the H19△H19 allele using primers (Figure 2.14 and Tables 5.1 and 5.2). The H19△H19
allele is maintained/backcrossed in B6 background via paternal transmission.
5.3 Gene Expression Analysis
Sample collection and processing
All mouse tissue samples were flash-frozen in liquid nitrogen and stored at -80°C.
Tissues were processed using the polytron homogenizer for the neonatal liver and
tongue samples, or syringes and needles for the embryonic liver and placenta samples.
iPSCs were manually dislodged from plates using pipette tips or cell scrapers
and EBs were dissociated using 0.25% Trypsin-EDTA. iPSCs were pelleted and stored
at -80°C. The dissociated EB samples were pelleted, put in 1ml of TRIzol, incubated at

room temperature for 10min, then stored at -80°C.
RNA isolation and cDNA synthesis
RNA from mouse tissues, iPSCs, and EBs was isolated using TRIzol according
to the manufacturer’s instructions. RNA was precipitated using glycogen and 100%
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isopropanol. Isolated RNA was treated with DNase (Promega) to remove genomic DNA
contamination and cDNA was synthesized using Superscript III reverse transcriptase
(Invitrogen) and random primers (Roche).
Allele-specific expression
10ng of cDNA was used for allele-specific expression assay. Allele-specific
expression of H19 and Igf2 was determined by RT-PCR followed by restriction digestion
using RFLP between the B6 and CAST alleles. H19 RT-PCR fragment was digested
with Cac8I, and Igf2 RT-PCR fragment was digested with MluCI for 3 hours at 37°C.
Primers and PCR conditions are listed in Tables 5.2 and 5.3.
Total expression
5ng of cDNA was used for qRT-PCR assay. Power SYBR Green mater mix
(Applied Biosystems) and primers in final concentration of 0.2μM were used on an ABI
7300 machine. Each sample was run in triplicate, and the mean value of triplicate is
plotted in graphs. For each primer set, reaction efficiency (E) was calculated using
standard curve, and E^-Ct value of each gene was normalized to E^-Ct values of
housekeeping genes.
For analyses in mouse samples, total expression levels of H19, Igf2, Igf1r, and
IGN genes were measured relative to the geometric mean of expression levels of Arbp,
Nono, and Rpl13a. For the y-axis on the graph, the mean value of +/+ is arbitrarily set as
1. For analyses in human samples, total expression levels of pluripotency markers, EB
markers, H19, and IGF2 were measured relative to the geometric mean of expression
levels of GAPDH and PPIG.
Total expression levels of miR-675-3p and miR-675-5p were determined relative
to the level of snoRNA202 by using a separate RT kit (TaqMan MicroRNA Reverse
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Transcription Kit, Thermo Fisher Scientific), qRT-PCR primers (Assay Id 001232,
001941, 001940, Thermo Fisher Scientific), and a PCR master mix (TaqMan Universal
PCR Master Mix, catalog number 4304437, Thermo Fisher Scientific) according to
manufacturer’s protocol. Primers and PCR conditions for all expression analyses are
listed in Tables 5.1, 5.2, and 5.7.
5.4 DNA Methylation Analysis
Sperm sample collection and preparation
H19hIC1/+ mouse mature sperm was collected from cauda epididymis and vas
deferens from minimum 8 weeks old, primed male mice. For the human sperm samples,
discarded semen samples were obtained from the University of Pennsylvania Fertility
Clinic following routine semen analysis. As all samples were discarded and de-identified,
the University of Pennsylvania Institutional Review Board determined this study was
exempt from requiring informed consent. Semen samples were washed with PBS to
remove seminal fluid. The resulting human sperm were somatic cell lysed (0.1% SDS,
0.5% Triton-X-100) for 30min on ice, counted, and stored at -80°C until further use.
gDNA isolation
Collected mouse neonatal and embryonic tissues, human fibroblasts, iPSCs, and
EBs were first digested with 12μl of 20mg/ml proteinase K (Sigma-Aldrich) in 500μl lysis
buffer (50mM Tris, pH8.0, 100mM EDTA, 0.5% SDS) overnight at 55°C. For both mouse
and human sperm, 500μl sperm-specific lysis buffer (20mM Tris-HCl pH8.0, 20mM
EDTA, 4% SDS, 200mM NaCl) was used and 5μl of 2-mercaptoethanol (Sigma-Aldrich)
was added, in addition to the 12μl of 20mg/ml proteinase K.
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For all samples, gDNA was isolated using Phenol:Chloroform:Isoamyl Alcohol
(Sigma-Aldrich P3803) and ethanol precipitation with 7.5M ammonium acetate. All
isolated gDNA samples were resuspended in water and stored at-20°C or resuspended
in 1xTE and stored at 4°C.
Bisulfite treatment
For mouse neonatal and embryonic tissues, mouse and human sperm samples,
and iPSCs, 250-1000ng of gDNA was subjected to bisulfite mutagenesis using the
Epitect kit (Qiagen) according to the manufacturer’s protocol. Pools of 120-200 oocytes
were collected from 25-28 days old heterozygote (H19hIC1/+) female mice and pools of
40-50 two-cell embryos were collected by crossing H19hIC1/+ male mice to superovulated
WT B6 female mice. Blastocyst was individually collected (single blastocyst was used as
a single data point). Oocytes, two-cell embryos, and blastocysts were subjected to
bisulfite mutagenesis using the Epitect plus kit (Qiagen) according to manufacturer’s
protocol.
20-25ng bisulfite-mutagenized DNA (for mouse neonatal and embryonic tissues,
mouse and human sperm samples, and iPSCs), 24-100 oocytes, ~18 two-cell embryos,
or half blastocyst equivalent of bisulfite-mutagenized DNA was used per PCR for
pyrosequencing, cloning and sequencing, and COBRA.
Pyrosequencing was performed as previously described (de Waal et al., 2014).
PCR for cloning and sequencing for the mIC1 was performed using nested PCR and
PCR beads as previously described (de Waal et al., 2014). PCR for cloning and
sequencing for the hIC1 was performed using PyroMark PCR Kit (Qiagen). For all
cloning and sequencing experiments, StrataClone, PCR cloning Kit (Agilent
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Technologies) was used. For COBRA, the amplified PCR products were digested with
appropriate restriction enzymes (HPYCH4IV for IC1, RsaI for IC2) for 3 hours at 37°C;
enzymes were then inactivated for 10 min at 65°C; bands were resolved using 12%
polyacrylamide gel and were quantified using ImageJ. For all PCR-based methylation
analyses, minimum of two rounds of PCR was performed per analysis, when enough
DNA was available. Primers, PCR conditions, and relevant restriction enzymes used for
all methylation analyses are listed in Tables 5.1, 5.3, 5.5, and 5.6.
5.5 Histology
Histology was performed as previously described (de Waal et al., 2015).
5.6 Mouse Spermatogenic Cell Fractionation
Round spermatid fraction of mouse spermatogenic cells were collected using
STA-PUT in two independent replicates and purity of each fraction was verified as
described in (Bryant et al., 2013, 2015) and per guidance of Dr. Lacey Luense. Each
collection used both testes of 12 heterozygous (H19hIC1/+) primed male mice. Purity of
each pool was measured as 87% (pool 1) and 86% (pool 2).
5.7 Isolation of mouse embryonic fibroblasts (MEFs)
MEFs were isolated from individual day 12.5 embryos in a B6 background as
previously described (Verona et al., 2008).
5.8 Chromatin Immunoprecipitation (ChIP)-qRT-PCR Analysis
ChIP was carried out as previously described in (Bryant et al., 2015) and as per
guidance of the protocol from the laboratory of Dr. Shelly Berger. Round spermatids and
MEFs were cross-linked using 1% formaldehyde in Phosphate-buffered saline (PBS) for
10 min at room temperature. The reaction was quenched using glycine at final
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concentration of 125mM for 5 min at room temperature. Cells were spun down at
1500rpm for 5min, washed with cold PBS(1X), and flash frozen in liquid nitrogen and
stored at -80°C until processed for ChIP. After cell lysis, lysates were sonicated using
Covaris S220 sonicator for 20 min with 5% duty cycle, 140 W of peak incident power,
200 cycles per burst, and 6°C bath temperature. 1/10 volume of 10% triton X-100 in PBS
was added to the sonicated lysate, and the lysate was spun at 14000rpm for 10 min at
4°C. Supernatant was saved. Protein content of the lysate was measured by the
bicinchoninic acid assay. For each IP, ~200μg of protein and 30μl of Dynabeads Protein
G (Thermo Fisher Scientific), with 2.5 to 5μg of IgG (Santa Cruz Biotechnology sc-2027),
H3 (Abcam ab1791), and H3K9me3 (Abcam ab8898), 5μl of H3K4me2 (EMD Millipore
07-030), or 10μl of CTCF (EMD Millipore 07-729) were used. Following elution of ChIP
DNA, qRT-PCR was performed as described in Chapter 5.3 using the Power SYBR
Green master mix and the ABI 7300 machine. For qRT-PCR, two different sets of primer
pairs were used for assays b and j (Figure 2.2C) and a mean value of the two primer
sets was plotted on the graph. All other assays used one set of primer pair. Each ChIP
signal was calculated as percent input of each IP normalized to non-specific IgG
(percent input IP - percent input IgG). ChIP-qRT-PCR primers are listed in Table 5.3.
5.9 Patient clinical features and genetic testing
Clinical information, clinical testing results, and fibroblast samples were collected
from the Children’s Hospital of Philadelphia BWS registry/repository (IRB #13-010658).
All four patients presented with hyperinsulinism, macrosomia, macroglossia,
omphalocele, and hemihyperplasia. Genome-wide single nucleotide polymorphism
(SNP) microarray analysis was carried out using the Illumina CRC BeadChip as
previously described (Conlin et al., 2010).
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5.10 iPSC generation and culture
* All reagents are from Life Technologies, unless otherwise specified first time
mentioned.
Fibroblast derivation and culture
Skin samples were collected during surgical procedures and fibroblasts were
dissociated using collagenase Type 2 (Worthington) in RPMI 1640 (1.6 g in 200 ml) for
30 minutes. In preparation for reprogramming, Patient 1, 2, 3 and 4 fibroblasts and
normal human fetal male fibroblasts IMR-91 (Coriell Institute for Medical Research) were
cultured in fibroblast media (RPMI with 20% fetal bovine serum (Hyclone SH30070.03),
1X penicillin/streptomycin, 1X GlutaMAX)) and fed every 2 days.
Viral Reprogramming
Patient 1 fibroblasts were reprogrammed with the infection of the inducible stem
cell cassette (STEMCCA) and reverse tetracycline-controlled transactivator (rtTA) virus
(Sommer et al., 2009) as previously described (Anguera et al., 2012; Woo et al., 2016).
5x104 Patient 1 fibroblasts were seeded onto one well of a 6-well plate. The following
day, in fibroblast media, cells were infected with STEMCCA (100μl) and rtTA (80μl)
viruses prepared by (Woo et al., 2016). Two days after infection, the media was replaced
with fresh fibroblast media. The following day, cells were passaged onto three 10 cm
gelatinized (0.1% gelatin) plates in fibroblast media with 2μg/ml doxycycline (Sigma
9891) and transferred to low oxygen (5%CO2, 4%O2) incubator (a portion of infected
cells were also plated onto 12-well plates -/+ 2μg/ml doxycycline (Sigma 9891) to test for
efficiency of infection by measuring OCT4 induction by immunohistochemistry, by
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method described below.) For subsequent days of reprogramming, cells were fed daily
with WIBR hES media (DMEM/F12 with 15% fetal bovine serum, 5% KnockoutTM Serum
Replacement, 0.1875% Sodium Bicarbonate, 1X nonessential amino acids, 1X
penicillin/streptomycin, 1X GlutaMAX, 0.1mM 2-mercaptoethanol, 10ng/ml βFGF (R&D

Systems)) and freshly added 2μg/ml doxycycline, as described (Woo et al., 2016).

Episomal reprogramming
Patient 2, 3, and 4 fibroblasts and IMR91 fibroblasts (Coriell Institute for Medical
Research Cell Repository) were reprogrammed with episomal plasmids as previously
described (Bershteyn et al., 2014; Okita et al., 2011). To reprogram, we electroporated
600,000 cells with plasmids (1μg of each) CXLE-hOCT3/4-shp53, pCXLE-sSK, pCXLEHUL, and pCXLE-EGFP plasmid (Okita et al., 2011) (Addgene) using the Neon®
Transfection System 100-ml-kit according to manufacturer’s instruction. Conditions for
electroporation were 1,650 V, 10ms, and three pulses (Bershteyn et al., 2014). As
described by (Okita et al., 2011), pCXLE-EGFP was used to monitor the efficiency of
electroporation and gradual loss of plasmid/eGFP expression with prolonged culture.
Cells were recovered in fibroblast media and plated onto 10 cm and 6 cm gelatinized
plates and incubated in a standard high oxygen incubator. The following day, media was
changed to the WIBR hES media, and plates were moved to a low oxygen incubator and
fed daily for 6 days. During initial 7 days of reprogramming of the patient fibroblast 3 and
4 and IMR91 fibroblasts, the WIBR hES media was supplemented with 37.5μg/ml
Vitamin C (VC) (Sigma 49752), based on analysis of (Chung et al., 2010) and
considering the amount of VC already in the KnockoutTM Serum Replacement (Stadtfeld
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et al., 2012). On the 7th day after electroporation, fibroblasts were expanded onto
multiple 6 cm and 10 cm gelatinized plates and fed daily with WIBR hES media,
analogous to our viral reprogramming method (Woo et al., 2016).
Picking and culturing iPSCs
Colonies were picked between day 18 and 28 of reprogramming into media with
50% WIBR hES media and 50% serum free iPSC media (DMEMF12 with 20%
KnockoutTM Serum Replacement, 1X nonessential amino acids, 1X
penicillin/streptomycin, 1X GlutaMAX, 0.1mM b-mercaptoethanol, 10ng/ml βFGF (R&D
Systems)). Colonies were picked and passaged onto gelatin coated 6-well plates that
were plated with 125,000 Mitomycin C treated CF1 mouse embryonic
fibroblasts(MEFs)/well. Clones were weeded and fed every 1-2 days with serum free
iPSC media. iPSCs were manually passaged every 5-7 days. On the days of picking,
passaging wells with <5 colonies, and thawing iPSCs, 0.5mM ROCK inhibitor
(StemMACSTMThiazovivin) was routinely added to media; ROCK inhibitor was removed
the following day by changing to fresh media.
5.11 EB generation
* All reagents are from Life Technologies, unless otherwise specified first time
mentioned.
iPSCs were differentiated to EBs as previously described (Anguera et al., 2012).
iPSCs were dislodged from MEF feeder cells using pipette tips or cell scrapers and
transferred to low attachment plates (Corning) in 50% WIBR hES media and 50% EB
differentiation media (DMEMF12 with 20% fetal bovine serum, 1X nonessential amino
acids, 1X penicillin/streptomycin, 1X GlutaMAX, 0.1mM 2-mercaptoethanol). ROCK
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inhibitor was added for the first day of EB differentiation at final concentration of 0.5mM
and removed the next day by changing to fresh EB differentiation media. After 7 days,
EBs were transferred to gelatin-coated plates and cultured for 7 days. Media was
changed every other day. EBs were collected on day 14.
5.12 PCR Genotyping of fibroblasts and iPSC clones
Microsatellite marker AFM217YB10 was used to genotype parental alleles of
patient 1 and 2 gDNA. Single Nucleotide Polymorphisms (SNP) rs3741216 (T/A) in
patient 3 and rs10840159 (A/G) in patient 4 were used for genotyping iPSC clones,
facilitated by restriction enzyme digest of polymorphisms. See Table 5.4 for details.
5.13 Characterization of iPSCs
Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for
20min at room temperature, permeabilized in 0.1% Triton-X100 (EMD), blocked with 3%
bovine serum albumin (Calbiochem), and incubated overnight at 4°C in following primary
antibodies: SSEA1 (1:100, Millipore), SSEA3 (1:100, Millipore), SSEA4 (1:100, Millipore),
TRA1-60 (1:100, Millipore), TRA1-81 (1:100, Millipore) and Oct4 (1:250, Novus
biologicals). Cells were then incubated with appropriate secondary antibodies: Alexa
Fluor 488 goat anti-mouse IgG (1:1000, Life Technologies), Alexa Fluor goat anti-mouse
IgM (1:1000, Life Technologies) and FITC-goat α-rabbit IgG (1:1000, Novus biologicals)
for 30min at room temperature.
Karyotyping
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Cells were treated with 0.2ug/ml Colcemid (Sigma) for 4 hours at 37°C, collected
using 0.25% Trypsin and lysed in 0.56% (w/v) KCl for 25min at room temperature. Cells
were fixed in methanol:acetic acid (3:1) solution, spread to slides, stained with Giemsa
(Sigma).
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Table 5.1 PCR conditions for the H19hIC1 allele
Gene/
region
assayed
Genotyping
-

Tissue

All

Allele-specific expression
H19
P0 liver;
P0 tongue;
E15.5 liver;
E15.5
placenta;
E9.5 embryo

Igf2

P0 liver;
P0 tongue

E15.5 liver;
E15.5
placenta;
E9.5 embryo
E15.5
placenta;
E15.5 placenta
E9.5 embryo
Pyrosequencing
hIC1
All
(CTS6)

Genotype

All

2min denaturation at 94°C; # cycles
of 15sec at 94°C, 15sec at TA, and
20sec at 72°C; 2min extension at
72°C

WT, KI*

Annealing
Temp (°C)
(TA)

Cycle
number
(#)

58-60

35

60

26-30

2min denaturation at 95°C; # cycles
of 15sec at 95°C, 10sec at TA, and
20sec at 72°C; 5min extension at
72°C

WT, KI

27-29

WT

26-28
58

KI

All

All mouse
ICRs
except for
Snrpn ICR
Mouse
Snrpn ICR

31-33

15min denaturation at 95°C; #
cycles of 30sec at 95°C, 30sec at
TA, and 30sec at 72°C; 5min
extension at 72°C
15min denaturation at 95°C; #
cycles of 15sec at 95°C, 30sec at
TA, and 15sec at 72°C; 10min
extension at 72°C

55

45

55

45

58

Bisulfite sequencing
mIC1
All

hIC1
CTS1/2
hIC1 CTS3
hIC1 CTS4
hIC1 CTS6

PCR conditions

All

All

All

1st round: 2min denaturation at
94°C; # cycles of 30sec at 94°C,
30sec at TA, and 30sec at 72°C;
5min extension at 72°C

50

40

2nd round: 2min denaturation at
94°C; # cycles of 30sec at 94°C,
30sec at TA, and 30sec at 72°C;
5min extension at 72°C

58

35

15min denaturation at 95°C; #
cycles of 30sec at 95°C, 30sec at
TA, and 30sec at 72°C; 5min
extension at 72°C

58

45

60
58
55

41
41
45

*KI: hIC1 knock-in
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Table 5.2 Genotyping and expression analyses primers for mouse studies
Gene/region
Assayed

Primer name

Sequence

Reference

Genotyping
PGNeo0.2

CCACTTGTGTAGCGCCAAGTGCC

HSEQR1
HIC1SEQF1

CCACAGAGTCAGCATCCAC
CCTTCACGGCTTTGACACTC

TV23armSEQR1

GTCAACCGGAGGCACAGTAT

H19-214

TTGTGGTGAGGCTGTCTTTG

H19+2722

CCTATTCCCCATTCCATCCT

Thorvaldsen et al., 2002

This study

Allele-specific expression
H19
Igf2

HE2

TGATGGAGAGGACAGAAGGG

HE4

TTGATTCAGAACGAGACGGAC

Igf2-18

ATCTGTGACCTCTTGAGCAGG

Igf2-20

GGGTTGTTTAGAGCCAATCAA

De Waal et al., 2014

Total expression
Arbp
Nono
Rpl13a
H19
Igf2
Cdkn1c
Gtl2
Igf2r
Dlk1
Gnas
Peg3
Slc38a4
Igf1r

ArbpqPCRF

TCCCACTTACTGAAAAGGTCAAG

ArbpqPCRR

TCCGACTCTTCCTTTGCTTC

NonoqPCRF

GCTCGTGAGAAGCTGGAGAT

NonoqPCRR

TTCTTGACGTCTCATCAAATCC

Rpl13aqPCRF

ATCCCTCCACCCTATGACAA

Rpl13aqPCRR

GCCCCAGGTAAGCAAACTT

H19qPCRF

GTCTCGAAGAGCTCGGACTG

H19qPCRR

ACTGGCAGGCACATCCAC

Igf2qPCRF

CGCTTCAGTTTGTCTGTTCG

Igf2qPCRR

GCAGCACTCTTCCACGATG

Cdkn1cqPCRF

TCTCGGGGATTCCAGGAC

Cdkn1cqPCRR

ACGTTTGGAGAGGGACACC

Gtl2qPCRF

TTGCTGTTGTGCTCAGGTTC

Gtl2qPCRR

ATCCTGGGGTCCTCAGTCTT

Igf2rqPCRF

GCACAGAATCCAGACTAGCATTACA

Igf2rqPCRR

CCTCCTTATCAGCTTTAAATATGTCTTTCTT

Dlk1qPCRF

CGGGAAATTCTGCGAAATAG

Dlk1qPCRR

TGTGCAGGAGCATTCGTACT

Gnasexon1aqPCRF

AGCGCGAGGCCAACAAAA

Gnasexon1aqPCRR

GTGCGTGGCCCGGTAGA

Peg3qPCRF

GGTGTGTGCGTAGAGTGCTG

Peg3qPCRR

TCCTCTTGCCAGTTGTCTCC

Slc38a4qPCRF

TCACACTGCTGTTTCCAAGG

Slc38a4qPCRR

CAGCCGGAAGAATGAAAATC

Igf1rqPCRF

GTGGGGGCTCGTGTTTCTC

Igf1rqPCRR

GATCACCGTGCAGTTTTCCA
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This study

Plasschaert and
Bartolomei, 2014

This study
Weaver et al., 2010
This study
This study
Varrault et al., 2006
This study
Varrault et al., 2006
This study
Bloise et al., 2012
Keniry et al., 2012

Table 5.3 Methylation anlyses and ChIP-qRT-PCR primers for the H19hIC1 allele
Region
assayed
Pyrosequencing

Primer name

Sequence

Reference

hH19pyroseq2F
hIC1

Qiagen
Assay name ADS003
Catalog No PMC0007406

hH19pyroseq2Rbiotinylated
hH19pyroseq2
seq

For mouseIC1, Kcnq1ot1 ICR, Peg1 ICR, Peg3 ICR, Snrpn ICR, and IG-DMR, primers are described in (de Waal et
al., 2014).
Bisulfite sequencing
BMsp2t1
GAGTATTTAGGAGGTATAAGAATT
mIC1
BHha1t3
ATCAAAAACTAACATAAACCCCT
de Waal et al.,
BMsp2t2
GTAAGGAGATTATGTTTATTTTTGG
2014
BHha1t4
CCTCATTAATCCCATAACTAT
CTS1F
GTATTTTTGGAGGTTTTTTATTTAG
hIC1 CTS1/2
Beygo et al.,
CTS2R
TCCCATAAATATTCTATCCCTCACTA
2013
CTS3F
GGGAGATGAGATATTTTGGTGATAATG
hIC1 CTS3
CTS3R
CCCCATCCAAAAAAAACTTAAAC
CTS4F
TATAGGGTTTTTGGTAGGTTTA
hIC1 CTS4
CTS4R
CCATAAATATCCTATCCCTAATA
CTS6F
GTAGGGTTTTTGGTAGGTATAGAGT
hIC1 CTS6
Takai et al.,
CTS6R
CACTAAAAAAACAATTATCAATTC
2001
hH19pyroseq2F
hIC1 CTS6
Qiagen Assay name ADS003
(used for
hH19pyroseq2R
Catalog No PMC0007406
oocytes)
non-biotin
Non-biotinylated reverse primer was used
ChIP-qRT-PCR
mIC1

hIC1

mIC1chIPF2-assay b
mIC1chIPR2-assay b
mIC1chIPF3-assay b
mIC1chIPR3-assay b
mIC1chIPF4-assay c

AATGCCTGATCCCTTTGTTG
TACATATTGCTCGGCAGACG
AGCTTTGAGTACCCCAGGTTCA
GCCTCTGCTTTTATGGCTATGG
CTCTTTAGGTTTGGCGCAAT

mIC1chIPR4-assay c
hIC1chIPF1-assay j
hIC1chIPR1-assay j
hIC1chIPF2-assay j
hIC1chIPR2-assay j
hIC1chIPF4-assay i
hIC1chIPR4-assay i
hIC1chIPF5-assay k

GCCCTATTCTTGGACGTCTG
CTGATTCCAGCAGCACAGAG
GTGTGAGCCTGACAGTGCAT
GGTCCCAGTCATGATCACCT
CTGAAGCTGGGACAGGAGAG
CCCGAGGGTTGTCAGAGATA
CTCCCCAACCTTCAACAATG
ACAGAATCGGTTGTGGCTGT

hIC1chIPR5-assay k

AGCCTTGGGTCACCTTCAG
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This study
Delaval et al.,
2007
This study

This study

Table 5.4 Genotyping assays for iPSCs
Patient
Forward
cell linesa
Patient 1 GGGGCATCTGTGGCTA

Reverse

Patient 2

GGGGCATCTGTGGCTA

TCCGGTTTGGTTCAGG

Patient 3

AACACCTTAGGCTGGTGG

TCGGAGCTTCCAGACTAG

Restriction
Enzyme
Not
applicable
Not
applicable
MseIb

Patient 4

AACACCTTAGGCTGGTGG

TCGGAGCTTCCAGACTAG

MscIb

TCCGGTTTGGTTCAGG

a

Polymorphism
Assayed
AFM217YB10
AFM217YB10
rs3741216
This study
rs10840159

PCR conditions to assay Patients 1 and 2 microsatellite repeat marker: 94°C 2min, (94°C 30s, 57°C 30s,
72°C 30s)x35 cycles, 72°C 5min. To assay Patients 3 and 4 SNPs, PCR conditions are: 94°C 4min, (94°C
90s, 60°C 60s, 72°C 90s)x31 cycles.
bThe common (maternal) allele of patient 3 gDNA is digested with MseI at rs3741216 (T/A); the common
(maternal) allele of patient 9 gDNA is digested with MscI at rs10840159 (A/G).
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Table 5.5 PCR conditions for methylation analyses of iPSCs
Gene/
region assayed
Pyrosequencing
hIC1 (CTS6) and
SNRPN ICR

Restriction
enzyme

Not
applicable

PCR conditions

15min denaturation at 95°C; # cycles of 30sec
at 95°C, 30sec at TA, and 30sec at 72°C; 5min
extension at 72°C

IG-DMR and
MEG3-DMR
Bisulfite sequencing
hIC1 CTS3

Annealing
Temp (°C)
(TA)

Cycle
number
(#)

55

45

58

45

Not
applicable

15min denaturation at 95°C; # cycles of 30sec
at 95°C, 30sec at TA, and 30sec at 72°C; 5min
extension at 72°C

60

41

COBRA
IC1 (CTS3)

HPYCH4IV

15min denaturation at 95°C; # cycles of 30sec
at 95°C, 30sec at TA, and 30sec at 72°C; 5min
extension at 72°C

60

41

IC2

RsaI
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Table 5.6 Methylation analyses primers for iPSCs
Region
assayed
Primer name
Pyrosequencing
hH19pyroseq2F
hIC1
hH19pyroseq2Rbiotinylated
hH19pyroseq2
seq
CG4Assay1F
IG-DMR
CG4Assay1R
Assay1
CG4Assay1seq
CG4Assay2F
IG-DMR
CG4Assay2R
Assay2
CG4Assay2seq
CG7Assay1F
MEG3DMR
CG7Assay1R
Assay1
CG7Assay1seq
MEG3CG7Assay2F
DMR
CG7Assay2R
Assay2
CG7Assay2seq
SNRPN F
SNRPN
SNRPN
R
ICR
SNRPN seq1
SNRPN seq2
Bisulfite sequencing
CTS3F
hIC1
CTS3
CTS3R

Sequence

Reference

Qiagen
Assay name ADS003
Catalog No PMC0007406

5'Biotin- ATTATTGAATTGGGTTTGTTAGTAGT
ATCAAAACAACTCAAATCCTTTATAAC
CCTTTATAACAAATTAAAATATATC
GTTTTATTATTGAATTGGGTTTGTTAGTA
5'Biotin- ATCAAAACAACTCAAATCCTTTATAAC
AATTGGGTTTGTTAGTAG
5'Biotin- ATTATAGGGTGTTGGTTATGG

Kameswaran
et al., 2014

CCCCAAATTCTATAACAAATTACTCT
CAACAAAAAAAAAAAAAAAAAATTC
5'Biotin- TTAGATTGTAGTAAAGAAGGGAGGAAAAAA
CCCCCACACATTATACCTAAATTC
ATTATACCTAAATTCACCCT
5'Biotin- AGGGAGTTGGGATTTTTGTATT
CCCCAAACTATCTCTTAAAAAAAAC
ACACAACTAACCTTACCC
CCAACCTACCTCTAC

White et al.,
2006

GGGAGATGAGATATTTTGGTGATAATG
CCCCATCCAAAAAAAACTTAAAC

Beygo et al.,
2013

COBRA
IC1
(CTS3)

CTS3F

GGGAGATGAGATATTTTGGTGATAATG

CTS3R

CCCCATCCAAAAAAAACTTAAAC

IC2F

GGTAGGATTTTGTTGAGGAGTTTT

IC2R

CACACCCAACCAATACCTCATA

IC2

Beygo et al.,
2013

This study
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Table 5.7 qRT-PCR primers for iPSCs and EBs
Gene
Forward
Differentiation markers for embryonic body

Reverse

AFP

AGCTTGGTGGTGGATGAAAC

CCCTCTTCAGCAAAGCAGAC

GATA4

TCCCTCTTCCCTCCTCAAAT

TCAGCGTGTAAAGGCATCTG

HAND1

TGCCTGAGAAAGAGAACCAG

ATGGCAGGATGAACAAACAC

RUNX2

CACTCACTACCACACCTACC

GTCGCCAAACAGATTCATCC

NCAM1

ATGGAAACTCTATTAAAGTGAACCTG

TAGACCTCATACTCAGCATTCCAGT

FGF5

CGCTATGTCTTCCTCTTCTGC

CAAAACACTTAACATATTGGCTTCG

Pluripotency markers
OCT4
CGACCATCTGCCGCTTTG
SOX2
ACAGCAAATGACAGCTGCAAA
NANOG
CCAAAGGCAAACAACCCACTT
DNMT3B GGAAATTAGAATCAAGGAAATACGA
GDF3
CGCTTTCTCCCAGACCAA
TERT
GCCTTCAAGAGCCACGTC

GCCGCAGCTTACACATGTTCT
TCGGCATCGCGGTTTTT
CGGGACCTTGTCTTCCTTTTT
AATTTGTCTTGAGGCGCTTG
GGCAGACAGGTTAAAGTAGAGGAG
CCACGAACTGTCGCATGT

LIN28A

CTGATGCTCTGGCAGAAGTG

AAGCGCAGATCAAAAGGAGA

H19, IGF2, GAPDH, and PPIG
H19
GCAAGAAGCGGGTCTGTTT
IGF2
ACACCCTCCAGTTCGTCTGT
GAPDH
GTCGTGGAGTCCACTGGCGTC
PPIG
GAAGAGTGCGATCAAGAACCCATGAC
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